Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disorder
whose pathologic hallmark is the presence of neuronal cytoplasmic inclusions (NCIs). In
approximately 97% of ALS cases, NCIs are found to be TDP-43+. Rho-guanine nucleotide
exchange factor (RGNEF) has recently been implicated in ALS pathophysiology through its colocalization and coimmunoprecipitation with TDP-43+. RGNEF has also been shown to harbour
cytoprotective effects in the N-terminal region and is responsible for the regulation of low
molecular weight-neurofilament (NFL), intimately involved neural structure, through its
predicted RNA-binding domain (RBD). This study looked to purify constructs of RGNEF
through nickel immobilized metal affinity chromatography (Ni-IMAC) and validate the
previously documented functions of RGNEF ex-vivo. N-terminal constructs of RGNEF tended to
self-associate into higher order structure and did not display a direct interaction with TDP-43
through SPR. pMJ5922, an RBD construct, was successfully purified and did demonstrate RNAbinding ex-vivo, validating maintenance of functionality following purification.
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Summary for Lay Audience
Amyotrophic Lateral Sclerosis (ALS) is a progressive and fatal neurodegenerative
disorder for which the cause is often unknown. Progressive neurodegeneration is in part caused
by a combination of maladaptive protein and RNA processing. Typically, proteins involved in
these defective systems are RNA-binding proteins (RBPs). One such protein is Tar DNA-binding
protein-43 (TDP-43), whose involvement in ALS pathologic mechanisms leads to its aggregation
and formation of neuronal cytoplasmic inclusions (NCIs). TDP-43 has been shown to co-localize
with a secondary protein, Rho-guanine nucleotide exchange factor (RGNEF), in ALS-affected
cells. Expression of RGNEF within cells typically helps with cell survival and the regulation of
important structural protein RNA. Association of RGNEF into the NCIs may decrease these
functions. In this study, segments of RGNEF were purified and tested to determine biophysical
characteristics and if function could be maintained outside of the cell. Tests showed that with a
small segment of RGNEF, TDP-43 did not interact directly. This segment of the protein also
tended to self-associate into larger structures. A second segment of RGNEF did display binding
to RNA, validating this function outside of a cellular environment.
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Dedication
I would like to dedicate this work to all the immensely strong individuals afflicted by
ALS. Your courage and stories are what pushed me to continue this research even when it
seemed insurmountable. Every day we are making progress in the fight against this disease.
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Chapter 1 – Introduction
1.1 Clinical Relevance of ALS
1.1.1 History
Amyotrophic later sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive
neurodegenerative disease of the motor neurons. Described previously by several prominent
anatomists and neurologists of the 1800s, the disease was first coined in 1874 by Dr. Jean-Martin
Charcot based on his series of case studies between 1865 to 18691. His term aptly detailed the
physiological presentation of ALS: muscle wasting due to decreased electrical input to the
muscle cell from motor neurons housed within the anterior horn of the spinal cord. Disease
progression correlates with increased motoneuron (MN) death, causing sclerotic plaque
formation in the spinal cord, further inhibiting remaining electrical impulses, and increasing
muscle atrophy.
1.1.2 Clinical Presentation
Since 1874 our knowledge of ALS has become increasingly comprehensive. ALS is now
understood to affect various neuronal populations, including both upper and lower motor neurons
(UMN and LMN), and occasionally those within the frontal and temporal lobes. UMN
involvement comprises affliction of corticopontine and corticospinal MNs, with symptomatology
reflective of difficulties in signal transduction to LMNs. Patients generally display slowed
activation of the muscles with increased stiffness and spasticity, as well as recovery of the
Babinski reflex2. LMN involvement afflicts MNs of the spinal cord and brainstem, with patients
displaying fasciculations of muscle cells directly connected to diseased LMNs in early stages,
followed by progressive paralysis and atrophy of the muscle cell3. Depending on the populations
involved and degree of involvement, initial presentation varies and can be classified as one of the
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following: Primary Lateral Sclerosis (PLS), progressive muscle atrophy (PMA), limb-onset ALS
with combined involvement, or bulbar-onset ALS (bALS)4. PLS can be defined as “progressive
UMN dysfunction in the absence of clinical signs of LMN involvement”5. If LMN involvement
becomes apparent, patients will be diagnosed with ALS. In contrast, patients with PMA initially
present with signs of solely LMN degeneration and associated muscle atrophy 4. Progressive
signs of UMN involvement render a later diagnosis of ALS, or ALS may be diagnosed postmortem via autopsy finding of UMN degeneration. Limb-onset ALS with combined UMN and
LMN involvement can be thought of as a classic presentation of ALS; patients display symptoms
of both LMN and UMN degeneration beginning in the extremities and progressing toward the
body-center4. bALS differs from the aforementioned subtypes as initial signs of disease are
visualized as dysfunction of the MNs of oropharyngeal musculature, causing dysarthria and
dysphagia. While 70% of those diagnosed with ALS have spinal-onset subtypes, referring to the
loss of function beginning in the extremities with an inward progression, 30% are diagnosed with
bALS6. It has also been noted that the specific neuropathology of bALS may increase the chance
of cognitive and language deficits related to frontotemporal neuron degeneration, occasionally
leading to a comorbid diagnosis of frontotemporal lobe dementia (FTLD)6.
1.1.3 Diagnosis, Epidemiology, and Current Therapeutics
Apart from genetic sequencing in cases of inherited ALS, diagnostic techniques have
remained relatively unchanged in recent decades relying heavily on an exclusion-based criteria
for other possible conditions. As no biomarkers for ALS are currently available for standardized
laboratory testing, definitive diagnosis can only be made post-mortem via MN biopsy. However,
common techniques such as laboratory testing, magnetic resonance imaging, cerebrospinal fluid
analysis, and electrophysiological studies can be used to rule out differential diagnoses with
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overlapping symptoms. Namely, these can include Myasthenia Gravis, Guillan-Barré Syndrome,
Lyme Disease, vitamin deficiency, heavy metal poisoning, various neuropathies and myopathies,
among others4. Patient demographics and history must also be taken into consideration when
exploring differential diagnoses of ALS.
ALS has an incidence rate of 2.4-3.0 per 100 000 per annum with a lifetime risk of 1:350
and 1:400 for men and women, respectively6. Disease onset is typically seen between 55 and 65,
but can been seen in patients as young as late teens; frequently, cases seen earlier in life are the
result of inherited familial ALS (fALS)6. The insidious and rapid progression of ALS lends itself
to grim prognoses: life expectancy of patients following diagnosis ranges from 2 to 5 years4. This
expectancy decreases with increased age of onset, early respiratory dysfunction, or initial bALS
presentation4. Due to the progressive muscle atrophy associated with ALS, weakening
respiratory muscles eventually lead to resting dyspnea and respiratory failure, frequently
preceded, and exacerbated, by pneumonia6.
Despite being the most frequently diagnosed MN disease, only two disease-modifying
drug exists for the treatment of ALS7. This is largely reflective of the still unclear aetiology and
pathophysiology of the disease. Riluzole, a glutamate antagonist, was approved for used by the
FDA in 19948. In two randomized control trials between seven countries in North America and
Europe, a 100mg daily dose of Riluzole was shown to significantly delay death or tracheostomy
by 2-3 months, with the greatest delay seen during late-stage ALS8,9. Mortality rates remained
unchanged. The precise mechanism of action of Riluzole is unknown, but most likely contributes
to inhibition of glutamate release at the synaptic cleft of MNs, inhibition of voltage dependent
sodium channels, or inhibition of intracellular events proceeding neuronal10. Glutamate
excitotoxicity results in excessive influx of calcium-ions to the cell, damaging RNA and DNA,
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as well as mitochondria. High levels of damage result in spilling of mitochondrial reactive
oxygen species (ROS) and subsequent cellular death. Edaravone, a small molecule antioxidant,
was approved for the treatment of ALS by the FDA in 20177. A series of Phase II and III RCTs
in Japan demonstrated intravenous administration of 60mg edaravone daily, for 10 days per
month, and over a period of 6 months, can slow the physical decline of early-stage ALS patients
by 33%11,12. Edaravone is believed to function as a ROS scavenger, minimizing MN and
neighbouring glial cell death, though officially defined as an unknown mechanism7.

1.2 TDP-43 and Other Genetic Markers
Research into the genetics of ALS was largely limited until development of genome
sequencing. In 1993, SOD1 became the first gene implicated in ALS, shown to harbour
causative, dominantly inherited mutations13. Since then, over 25 genes and 120 genetic variants
have been associated with ALS; though the process to determine causality is rigorous14. Due to
the diverse genetic biology of individuals and aetiology of ALS, causative mutations must be
validated through reproduction of fALS and sporadic ALS genetic studies, as well as animal
modelling. Mutations in each of these genes generally affect one or more of the following
categories: RNA metabolism, protein homeostasis, cytoskeletal dynamics, and glutamate
excitotoxicity. Despite the genetic diversity of patients, what is common within 97% of ALS
cases is the propensity of TDP-43 to aggregate into toxic neuronal cytoplasmic inclusions (NCIs)
and affect the cellular functions listed above15. TDP-43 is an RNA-splicing protein encoded by
TARDBP. Generally found within the nucleus due to a NLS where it exerts RNA regulatory
functions, TDP-43 is also capable of nucleocytoplasmic shuttling where it can regulate protein
synthesis of dendritic component proteins15. ALS-associated mutations in TARDBP are typically
missense and can cause increased localization to the cytoplasm or overexpression, leading to an
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abundance within the cytoplasm14. Mutated TARDBP also has a significantly higher chance of
misfolding14. These mutations occur at a low frequency, albeit causative of ALS16. The high
incidence rate of TDP-43 proteinopathy and relatively low mutation frequency suggests it plays a
critical role in disease progression regardless of aetiology. Understanding the mechanism by
which TDP-43 proteinopathy dampens many essential cellular processes may be crucial to the
development of new ALS therapeutics which do not target glutamate excitoxicity. Genes with
mutations known to cause ALS which are discussed in this paper are shown in Table 1.
Table 1. Several genetic mutations have been shown to be causative of ALS. Functional repercussions of
these mutations generally influence glutamate excitotoxicity, cytoskeletal dynamics, protein homeostasis,
and RNA metabolism, demonstrating the various pathogenic pathways of ALS.
Gene

Pathogenic Mechanism

Original Study

PFN1

Cytoskeletal dynamics

Wu et al., 201217

TUB4A

Cytoskeletal dynamics

Smith et al., 201418

DCTN1

Cytoskeletal dynamics

Munch et al., 200419

SOD1

Glutamate excitotoxicity, protein
homeostasis

Rosen et al., 199320

TARDBP

Cytoskeletal dynamics, protein
homeostasis, RNA metabolism

Kabashi et al., 200821

FUS

Protein homeostasis, RNA
metabolism

Kwiatkowski et al., 200922

UBQLN2

Protein homeostasis

Deng et al., 201123

VCP

Protein homeostasis

Johnson et al., 201024

OPTN

Protein homeostasis

Maruyama et al., 201025

C9orf72

RNA metabolism

Renton et al., 201126

1.2.1 Glutamate Excitotoxicity
Glutamate is the primary neurotransmitter within mammalian MN system, acting on
NMDA and AMPA receptors. As previously mentioned (1.1.3 Diagnosis, Epidemiology, and
Current Therapeutics), the inability to properly clear glutamate from the synaptic cleft or overrelease of glutamate results in hyperexcitation of the postsynaptic neuron, increasing ionized
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calcium (Ca2+) influx to disrupt mitochondrial function and increase cellular ROS production.
This excitotoxicity has been implicated in numerous neurodegenerative diseases, not limited to
ALS27.
Excitatory glutamate signalling via AMPA is reliant on proper AMPA receptor
production, comprised of four heterogenous subunits GluA1-428. The GluA2 subunit is
responsible for mediating Ca2+ permeability from the extracellular environment, preventing
hyperexcitation of the post-synaptic neuron28. Post-transcriptional editing of GluA2 mRNA by
adenosine deaminating acting on RNA2 (ADAR2) is required to maintain an adequate barrier to
Ca2+ within the AMPA receptor; decreased expression of ADAR2 and Glu2 editing have been
shown to occur at significantly lower levels in ALS patients, perpetuating AMPA receptor
activation28. Interestingly, lower expression of ADAR2 also correlated with increased TDP-43
NCI development28. Clearance of glutamate from the synaptic cleft is mediated in part by
excitatory amino acid transporter 2 (EAAT2), secreted from nearby astrocytes28. Expression of
mutant astrocytic SOD1, a dismutase with over 170 known ALS associated genetic variation,
correlates with up to a 95% decrease of EAAT2 protein levels in sporadic ALS post-mortem
analyses, however mRNA remained normal, suggesting translational deficits29. While it is
noteworthy that the only FDA approved pharmaceuticals for the treatment of ALS act in what
are hypothesized to be mechanisms involving glutamatergic signalling, no other antiglutamateric
drugs have demonstrated clinically significant effects, suggesting high involvement of other
pathogenic mechanisms28.
1.2.2 Cytoskeletal Dynamics and Axonal Trafficking
Proper maintenance of cytoskeletal dynamics is incredibly important within neurons due
to the high level of cellular polarization; polar architecture and placement of cellular organelles
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means that most protein synthesis occurs at local levels, following transportation of required
substrates from the soma. Inadequate transport leaves more distal locations, such as the synapse,
unable to properly translate proteins or produce neurotransmitters essential to signal
transduction. Particularly in MNs where axons may stretch up to 1m before forming the
presynaptic terminal, transport must remain efficient for neural function and communication
from motor cortices to muscle cells. Neurofilament (NF) is the primary intermediate filament
within the axon; disorganization of the NF network has been widely reported in fALS and sALS,
alike14. NF also participates in cross-bridging to actin filaments and microtubules, forming
interdisciplinary structural support within the axon30. Actin filaments are polymerized with the
assistance of actin binding proteins profilin I and II; as such mutations in the encoding PFN1
gene hinder actin filament production, dampening the structural integrity of the axon and
capacity for anterograde and retrograde microtubule dependent transport31,32. Appropriately,
PFN1 mutations are associated with ALS and produce ALS phenotypes in murine models32.
Microtubule mutations have also been associated with ALS; comprised of alpha and betatubulin, microtubules create a polarized dimer for anterograde and retrograde transport. Genome
sequencing of fALS patients revealed that TUBA4A mutations, coding for alpha-tubulin, lead to
decreased polymerization, general cytoskeletal destabilization, and downstream
neurodegeneration18. Facilitation of substrate transport along microtubule pathways is
accomplished in part through the dynein/dynactin complex. Mutations in DCTN1, encoding a
subunit of the dynactin complex, decreases the attachment efficiency of dynactin to
microtubules, impeding retrograde dynein-mediate transport33. These mutations were shown to
be causative of ALS in a wide-screen genome sequencing study33. While trafficking of larger
cargo such as vesicles and organelles is the functional responsibility proteins such as dynein and
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dynactin, movement of mRNA and other protein synthesis factors along the axon towards the
presynaptic cleft is facilitated by RNA granules. RNA binding proteins regulate the occupancy
and movement of these transport granules along the microtubule network. One such RBP is
TDP-43, who’s interactome includes numerous proteins rooted in synaptic function34.
Fluorescent imaging studies have demonstrated that cytoplasmic wild-type (WT)-TDP-43 can be
localized not only within the soma of MNs, but along the length of the axon up to the presynaptic
cleft35. However, expression of ALS-mutant TDP-43 significantly decreases the level of
anterograde transport, leading to an accumulation of both mutant TDP-43 and RNA within the
soma35. Though the mechanism through which mutations in TDP-43 result in decreased
transport, the possibility can be considered that TDP-43 loss of function (LOF) results in
perturbations of synaptic protein synthesis and subsequent neurodegeneration.
1.2.3 Protein Homeostasis
In non-pathologic states, protein homeostasis is maintained through careful balance of
protein expression, degradation, and recycling, relying on a variety of pathways: the ubiquitin
proteasomal system (UPS) for smaller, short-lived, soluble protein; autophagy, for larger, longlived proteins, protein aggregates, or organelles; and endoplasmic reticulum refolding.
Dampening of these pathways results in accumulation of misfolded proteins within the cytosol,
growing upon themselves to become cytoplasmic inclusions. These cytoplasmic inclusions,
found within the cytosol of MNs and muscle cells, are a hallmark of ALS.
Classically thought of as an accumulation of misfolded intermediate filaments such as NF
resulting from neural degeneration, it is now widely accepted that there exist two populations of
NCI: that of intermediate filaments, and the novel RNA-binding protein (RBP) NCI.
Interestingly, the two populations seem to be interconnected – proteins that regulate intermediate
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filaments and other dendritic and axonal protein expression through mRNA binding are indeed
the proteins that comprise the RBP NCIs36. Most frequently these proteins include FUS, SOD1,
and TDP43. TDP-43+ NCIs are notably pervasive and occur in 97% of ALS cases15. The
sequestering of RBPs typically responsible for the regulation of neural integrity proteins into
NCIs is suggestive of pathologic depletion of functional cytoplasmic protein preceding
downstream deficits in neuronal integrity and subsequent neurodegeneration. However, the
physical presence of NCIs within the cytoplasm has deleterious effects as well. Reflective of the
maladaptive protein degradation seen in ALS, NCIs promote further cellular distress once
formed, evoking stress response pathways and secretion of inflammatory molecules creating a
cytotoxic environment for both MNs and support cells alike.
Mutant SOD1 is prone to aggregation at significantly higher rates than its WT compart
and can perpetuate the aggregation of both mutant and WT-SOD1 in a prion-like manner37.
Similarly, mutated forms of FUS and TDP-43 can also display a prion-like mechanism of
mutant-propagated aggregation38. This is particularly troublesome in cases where TDP-43
mutations cause overexpression of the protein. ALS-associated mutations in TDP-43 causing
overexpression and favourable nucleocytoplasmic shuttling, lead to an abundance of aggregateprone protein within the cytoplasm. Overloaded degradative pathways, which would otherwise
clear excess TDP-43 through autophagy, become futile resulting in the generation of TDP-43containing NCIs15. Post-mortem analysis of ALS patient spinal cord and affected cortical areas
display TDP-43+ NCIs in 97% of cases. These aggregates are also capable of sequestering
chaperone proteins and ubiquilin, key players in the UPS pathway, adding to aberrant protein
build up28. It is then not far-reaching to assume that mutations of UPS- or autophagy-involved
proteins may provoke ALS-like pathology. In fact, mutations of ubilquilin2, vaslon-containing
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protein, and optineurin – all involved with either proteasome or autophagosome-mediated
proteolysis – have been linked to ALS28.
In non-pathologic states, misfolded protein may also be transported to the endoplasmic
reticulum, unfolded, and refolded into proper conformation with the assistance of endoplasmic
reticulum chaperone proteins39. This process is termed the unfolded protein response (UPR). In
diseased states such as ALS where there is an accumulation of misfolded protein, endoplasmic
reticulum associated degradation (ERAD) and lysosomal degradation is employed to assist with
the increased burden39. If protein burden remains high, UPR activity becomes analogous to
constitutively active, increasing the levels of apoptotic signalling molecules from the pathway,
and terminating in cell death40. Mutant SOD1 has also been shown to bind to integral membrane
endoplasmic reticulum protein derlin-1, a subunit of Complex 2 of the ERAD control system41.
The resulting decrease in ERAD efficacy hastens the acuity of UPR-related apoptotic signalling.
As such, there is fluidity and heterogeneity in the pathways promoting toxic cytosolic protein
aggregation in ALS.
1.2.4 RNA Metabolism
TDP-43 and FUS are important RBPs heavily involved with ALS pathogenesis.
Previously mentioned to have a strong propensity to misfold and aggregate, producing toxic NCI
build up for MNs and muscle cells, their consequent LOF has downstream effects on RNA
processing38. Many of their RNA targets, in fact, code for proteins involved in neuronal
physiology including dendritic growth and synaptic plasticity; loss of regulation and processing
of these target RNA therein supresses neural adaptive mechanisms28. Mutations in C9orf72, a
poorly defined open reading frame (ORF) most likely encoding a not yet recognized guanine
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exchange factor (GEF), cause additional aberrance of RNA metabolism by generating RNA
repeats and toxic RNA foci which sequesters both TDP-43 and FUS28.
Mutated TDP-43 has a strong propensity to aggregate and induce self-propagated
aggregation of both mutant and WT protein. However, TDP-43 mediated toxicity is not limited
to its effects on protein homeostasis – as an RNA-binding protein, TDP-43 is responsible for
regulating the levels of nearly one-third of the transcriptome42. Consequently, mutations do not
only cause the buildup of TDP-43+ NCIs, but also alter the fate of many RNA products.
Preferential cytoplasmic localization of mutated TDP-43 undermines the capacity for RNA
regulatory tasks, to the detriment of neurons. A 2011 study by Moran et al.34 which
experimentally decreased the levels of TDP-43 expressed within the brains of adult mice
revealed through massively parallel sequencing that as many as 601 mRNA targets had altered
levels of expression. Additionally, 965 altered splicing events occurred due to the loss of TDP-43
splicing activity. The majority of affected targets were products of genes encoding proteins
involved in synaptic activity, adding to the dysfunctional environment within the neuron34. While
mutations in TARDBP can directly cause TDP-43 LOF, the consequence of cell-wide TDP-43
proteinopathy and aggregation is an indirect LOF as well.
The discovery of ALS-associated mutations in TDP-43 lead to the idea that other RNA
binding proteins may also play a role in the pathogenesis of ALS, and that aberrant RNA
metabolism may be a key mechanism in disease progression. Subsequent research unveiled ALSassociated mutations in FUS. Both are designated as heterogenous nuclear ribonucleoproteins, a
class of RBPs responsible for diverse, multilevel regulation of RNA metabolism, corroborating
the theory of disordered RNA metabolism43. The function of FUS largely mirrors TDP-43: an
RBP mostly constrained to the nucleus due to a NLS with a functional role in RNA metabolism
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and DNA repair. A small fraction of FUS is localized within the cytoplasm of the axon and
presynaptic terminal where it regulates translation44. RNA targets of FUS have similar roles to
that of TDP-43, generally dendritic and synaptic component proteins, however the interactomes
themselves overlap minimally44. Mutations in FUS associated with ALS are typically dominant
and result in pathologic loss of RNA regulation essential to neural integrity and downstream
neurodegeneration, akin to TDP-43 mutations44.
C9orf72 is also heavily implicated in dysfunctional RNA processing metabolism related
to ALS. The most common mutations associated with C9orf72 is a G4C2 hexanucleotide repeat
expansion28. While a genotypical person would normally house 2-23 G4C2 repeats within the
ORF, patients with C9-associated ALS may carry hundreds to thousands14. The pathogenic
potential for a repeat expansion typically presents in one of three ways: haploinsufficiency due to
repeat expansion mutation within the protein, toxic proteinopathy due to accumulation of mutant
protein within the system, or toxic RNA build up42. Patients with ALS often have lower C9orf72
expression, consistent with haploinsufficiency, however a 2015 study by Koppers et al.45
demonstrated that C9orf72 antisense knockout mice did not display deficits in motor function or
behaviour. Additionally, motor cortices and fontotemporal cortical areas did not display any
phenotype of ALS pathology, nor did the spinal cord, decreasing the chance that C9orf72 LOF is
a driver of ALS. In contrast, adeno-associated viral introduction of G4C2 66-repeat expansion
C9orf72 induced neurodegeneration, and ALS/FTD behavioural deficits in murine models46.
Interestingly, introduction of the G4C2 66-repeat also induced TDP-43 proteinopathy, garnering
further support for TDP-43 as a key pathogenic mechanism of ALS. The transcription of repeat
RNA can also produce toxic nuclear and cytosolic RNA foci, sequestering RNA binding proteins
into foci and disrupting RNA processing and metabolism42. The G4C2 repeat in fact can be
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transcribed bidirectionally, giving rise to both G4C2 and C4G2 repeat RNA; antisense C4G2 foci
densely pack the nuclear region and increase the propensity of TDP-43 cytosolic mislocalization,
while G4C2 species are more stable within the cytosol and able to form a G-quadraplex
secondary structure28, 42. The stable G-quadruplex increases capacity of the foci to travel more
distally within the cell and accrue local RBPs, possible disrupting local translation47.

1.3 Physiological Relevance of RGNEF
1.3.1 Description
Rho-guanine nucleotide exchange factor (RGNEF) is an approximately 190 kDa protein
in the Dbl homology family of guanine exchange factor (GEF) proteins48. It is comprised of 5
major functional domains which regulate its bifunctionalism as both a GEF protein and RBP; the
amino terminus contains a leucine rich (LeuR) region and a zinc binding domain, the carboxyl
half contains conserved Dbl and Plekstrin homology domains, and an RNA-binding domain
(Figure 1)48. First discovered in the cerebral cDNA of a mouse model, RGNEF is now known to
be expressed in both the human brain and spinal cord, harnessing its functionality as an RBP
through association with the 3’-untranslated region of low molecular weight-NF (NFL) mRNA
and acting as a destabilizer49,50. Overexpression of RGNEF is known to decrease levels of
translated NFL to the detriment of the neuron, compromising structural integrity50. More
recently, murine and cell-based studies have demonstrated that RGNEF is a stress response
protein harbouring pro-survival effects51. RGNEF recruitment to RBP NCIs represents a possible
mechanism for a loss of cytoprotective effects which could otherwise mitigate pathogenesis in
ALS.
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Figure 1. Map of RGNEF with predicted functional domains.

1.3.2 Proposed implications RGNEF proteinopathy in ALS
Similar to RBPs like SOD1, FUS, and TDP-43, RGNEF has been implicated in the
pathophysiology of ALS, though the mechanism by which it perpetuates disease remains
unclear49. A small number of fALS cases have been tied to frameshift mutations in RGNEF,
resulting in a truncated version of the protein with a high propensity to aggregate52. However,
fALS cases represent a small fraction of ALS case incidence, and RGNEF pathology has not
been limited to fALS. Indeed, RGNEF has been shown to colocalize with the TDP-43, FUS, or
Corf72 containing NCIs.
Immunohistochemical imaging has depicted the presence of both TDP-43 and RGNEF
colocalizing within spinal motor neuron NCIs of ALS patients, confirming their interaction
through co-immunoprecipitation36. As such, it is becoming increasingly evident that the
dysfunctional metabolism of RBPs is an essential factor in ALS disease progression, particularly
that of TDP-43 and associated RGNEF. Further support for coinciding altered TDP-43 and
RGNEF metabolism is garnered through an in-vivo study by Droppelmann, et al.53 wherein
HEK293T cells with lactate-induced metabolic stress displayed significantly increased
cytoplasmic micronuclei containing both TDP-43 and either full length RGNEF or truncated
RGNEF with only the LeuR domain. Accordingly, interaction between TDP-43 and RGNEF
most likely depends on the N-terminal region of RGNEF within the LeuR domain, making it a
point of interest for the field. Recent findings regarding the LeuR domain of RGNEF continue
with evidence of cytoprotective characteristics in both murine and cell line models. Following
distal sciatic nerve injury in a mouse model, expression of RGNEF was markedly increased in
spinal cord motor neurons, suggesting that RGNEF acts as a stress-response protein51. In the
same study, HEK293T cells were used to validate stress response of RGNEF in murine models;
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cells were exposed to oxidative or osmotic stressors, and those transfected with full length
RGNEF displayed significantly lower percent cytotoxicity. Additionally, cells transfected with
truncated RGNEF lacking the LeuR domain conferred similar percent cytotoxicity to control
cells. This increase in cytotoxicity was not seen with recovery of the LeuR domain and
subsequent deletion of any remaining domains.
The RBD of the carboxyl-terminus of RGNEF has also been regarded as a possible
pathologic locale in ALS. Research has pointed to the aberrant function of RBPs as a key
mechanism in ALS pathogenesis and progression28. Additionally, regulatory disruption of NF
mRNA has been implicated in the neurodegeneration of ALS50. Fitting, the RGNEF RBD is
known to target the mRNA of NFL and regulate its stability50. Mouse models have demonstrated
that murine homologue p190RhoGEF binds the destabilizing region of NFL to stabilize the
transcript. This stabilization prevents the aggregation of NFL and subsequent decline in neuronal
structural integrity resulting from the loss of adequate protein levels. Sequestration of
p190RhoGEF effectively creates a LOF environment. In contrast, realization of the human
homologue demonstrated its function as a destabilizing factor for human NFL; overexpression of
RGNEF within HEK293T cell lines causes a significant decrease in levels of NFL mRNA as
measured using a luciferase probe50. Levels of NFL mRNA were recovered when using an
RGNEF construct lacking the RBD. The contrasting findings of these studies demonstrated the
need to further investigate the mechanism of RGNEF NFL regulation in pathologic and nonpathologic states, particularly as ALS is not a naturally occurring disease in mice.

1.4 Rationale and Significance
Previous research has demonstrated that RNA metabolism and the function of RBPs,
notably that of TDP-43 and RGNEF, is maladaptively altered in ALS and plays crucial role in
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disease progression28,53. Notably, TDP-43 has been demonstrated to be involved with a wide
range of pathogenic mechanisms and is highly colocalized with RGNEF – a protein which
typically confers cytoprotection and regulates levels of NFL53. It is then conceivable that the Nterminal associated cytoprotection of RGNEF may offer a therapeutic benefit to the down-stream
degenerative effects of TDP-43 positive NCIs. In turn, this may have far reaching implications
for a large population of ALS patients considering the prevalence of TDP-43 positive NCIs if it
is assumed RGNEF colocalizes with TDP-43 at the rate of TDP-43+ NCI occurrence,
approximately 97% of ALS cases. For this reason, determining the nature of the interaction
between RGNEF and TDP-43, as well as the physical structure of RGNEF, is paramount to
understand the recruitment and interaction between TDP-43 and RGNEF. The mechanism by
which RGNEF interacts and regulates NFL and other mRNA targets remains unclear, and
elucidation may hold further information surrounding the nature of structural degeneration in
ALS-affected MNs.

1.5 Experimental Approach and Aims
To further our understanding of the biophysical characteristics of RGNEF and the
interactome of the both N-terminal and C-terminal regions, truncated constructs of RGNEF will
be designed and expressed using E. coli competent cells. Expressed protein will be purified for
the purpose of analyzing biophysical properties using methods including thermal shift assay and
size exclusion chromatography-multiangle light scattering (SEC-MALS). Interaction between
RGNEF and TDP-43 will be tested via surface plasmon resonance (SPR) using purified RGNEF
constructs which will provide the first definitive evidence of whether a direct interaction between
the proteins exists.
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Chapter 2 - Methodology
2.1 Construct Design and Expression
2.1.1 Determination of construct perimeters and polymerase chain reaction (PCR)
Constructs were designed based on the sequence of a pUC-57 full-length RGNEF
plasmid codon-optimized for E. coli expression (hereon referred to as FL-RGNEF), synthesized
by BioBasic (Ontario, Canada).
Using Phyre2, a predictive secondary structure and homology modelling program, the
amino acid sequence of FL-RGNEF was input to determine regions of high confidence order or
disorder and predicted domain locations54. Regions with high confidence disorder were excluded
from constructs; regions with high confidence order were included. Regions of high confidence
order were concentrated around the 5 predicted functional domains of RGNEF and decreased
variably as distance from functional domains increased. As such, multiple constructs were
designed for each domain with a variety of termination locations. A total of 33 constructs were
designed; five went on to be used for this study (Figure 2A).
Constructs were produced via polymerase chain reaction using PrimeSTAR GLX DNA
polymerase (Takara Bio, California, USA). Forward and reverse PCR primers were designed for
each terminating sequence with an approximate initial melting temperature of 60 C. FL-RGNEF
was used as template DNA for each reaction. PCR reactions were completed using the
Eppendorf MasterCycler Pro (Ontario, Canada) staring at 98C for 5 min, proceeded by the
following 3-step protocol: 98 C for 10s, 60 C for 15s, 68 C for 5min, cycled 17 times.
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B
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C
Figure 2 A-C. RGNEF constructs were designed based on secondary structure predictions from Phyre254.
Structure prediction and disorder confidence vary along the Phyre2 colorimetric key of High (red) to Low
(indigo). Output for the predicted LeuR region is displayed in panel (B), output for predicted RBD is
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displayed in planel (C). Detailed in panel (A) are the boundaries of each truncation, with ranges indicated
in amino acids.
* Designates constructs used for the purpose of this study. The remainder were created and stored in the
Junop Lab Plasmid Library for future use.

2.1.2 Cloning and vectors
Using the Gateway Cloning (Thermo Scientific, United States) method as per
manufacture’s protocol, the PCR products for each construct were cloned into kanamycinresistant pDONR201 entry vector via BP reaction. Plasmids DNA was then combined with 50 L
of BL21DE3T1R E. coli competent cells, heat shocked for 50s in a water bath at 42 C and
cooled on ice for 2min. Cells were allowed to recover for 45min in a 37 C shaking incubator at
225rpm, with the addition of 50 L standard Lennox-Broth (LB) media. Cells were plated onto
kanamycin-LB-agar plates and left to grow overnight at 37 C. Single colonies were then selected
and grown in 10mL of kanamycin-inoculated LB media for 16-18h in a 37 C shaking incubator
at 225rpm. Plasmid DNA was purified using the QIAprep Spin Miniprep Kit (Qiagen, Ontario,
Canada) as per manufacturer’s protocol. A sample from each construct underwent restriction
enzyme digestion and subsequent agarose gel electrophoresis to validate sequence identity.
Sequence identity was then more carefully verified through DNA sequencing at the DNA
Sequencing Centre, Robarts Research, University of Western Ontario.
Entry of pDONR201 plasmid DNA into expression vectors was facilitated via LR
reaction, the second step of Gateway Cloning (Thermo Scientific, United States), completed as
per manufacture’s protocol. The DNA of each construct was placed into 2 expression vectors:
pDEST527 and pDEST566. pDEST527 contained a T7 promoter for desired gene expression and
N-terminal 6xHIS-tag attached to the entry gene by a short linker sequence for affinity
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chromatography. In light of literature suggesting the pervasive insolubility of RGNEF,
pDEST566 was selected as the second expression vector as it contained an N-terminal MBP6xHis fusion-tag for improved protein solubility during affinity chromatography purification.
Protein expression in the pDEST566 vector was as well under the control of a T7-promoter. LR
reaction products were mixed with 50 L of BL21DE3T1R competent cells, heat shocked for 50s
in a water bath at 42 C and cooled on ice for 2min. Cells were immediately plated on ampicillinLB-agar plated and incubated at 37 C overnight. The next morning, single colonies were then
selected and grown in 10mL of ampicillin-inoculated LB media for 16-18h in a 37 C shaking
incubator at 225rpm. Plasmid DNA was purified using the QIAprep Spin Miniprep Kit (Qiagen,
Ontario, Canada) as per manufacturer’s protocol and stored at -20C as expression plasmid stock.
Table 2 A-C display all RGNEF vectors produced by this method and used in this study.
Table 2 A-C. Donor (Table 2 A) and expression (Table 2 B, C) plasmids of RGNEF made using Gateway
Cloning, including forward (F) and reverse (R) primers which were used in conjunction with FL-RGNEF
during PCR to create each construct. X Denotes constructs which were unable to be produced to
completion during cloning due to mutation errors. * Denotes constructs which were used for the purpose
of this study.
A
Amino
Acid
Range

Plasmid

Primers (5’-3’)

1-395

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGCCTTCAATGTTGATATAGCTG

1-384

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCACTTGATCAATAACCATG

1-283
X

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACTCAAACGCTTTAACCAGG

1-275

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
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R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGATCCCAAAAATACTTACGG

1-219

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTCACATCTTCAACCAGC

1-109

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGGTTCGCTTGGG

1-94

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGTTGTCCACATAGGTAACGC

13-395

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGCCTTCAATGTTGATATAGCTG

13-384

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCACTTGATCAATAACCATG

13-283

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACTCAAACGCTTTAACCAGG

13-275

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGATCCCAAAAATACTTACGG

13-219

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTCACATCTTCAACCAGC

13-109

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGGTTCGCTTGGG

13-94

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGTTGTCCACATAGGTAACGC

94-395

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGCCTTCAATGTTGATATAGCTG

94-384

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCACTTGATCAATAACCATG

94-283

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACTCAAACGCTTTAACCAGG

94-275

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGATCCCAAAAATACTTACGG

94-219

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTCACATCTTCAACCAGC
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7841194

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTAGCCGTAGCCACA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCATTTTTCCTCCGGGCAG

8291194

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGGAGAGCTGGAGCCTG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCATTTTTCCTCCGGGCAG

11991731

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCGAGAGCGACGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAGTCAGATACACGATGTTCTCCT

11991578
X

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCGAGAGCGACGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTGTTGAAGCTCATCTGAAC

11991546

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCGAGAGCGACGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCGGCAGCAGAA

11991539
X

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCGAGAGCGACGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACAGGCTACGCTGACGA

13761731
X

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCAGCCAGAGCGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAGTCAGATACACGATGTTCTCCT

13761578

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCAGCCAGAGCGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTGTTGAAGCTCATCTGAAC

13761546

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCAGCCAGAGCGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCGGCAGCAGAA

13761539
X

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCAGCCAGAGCGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACAGGCTACGCTGACGA

14281731
X

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTGACGCGGATCG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAGTCAGATACACGATGTTCTCCT

14281578

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTGACGCGGATCG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTGTTGAAGCTCATCTGAAC

14281546

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTGACGCGGATCG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCGGCAGCAGAA

14281539
X

pDONR201 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTGACGCGGATCG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACAGGCTACGCTGACGA

B
Amino
Acid
Range

Construct Plasmid

Primers (5’-3’)
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1-395

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGCCTTCAATGTTGATATAGCTG

1-384
X

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCACTTGATCAATAACCATG

1-283
X

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACTCAAACGCTTTAACCAGG

1-275

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGATCCCAAAAATACTTACGG

1-219

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTCACATCTTCAACCAGC

1-109

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGGTTCGCTTGGG

1-94

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGTTGTCCACATAGGTAACGC

13-395

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGCCTTCAATGTTGATATAGCTG

13-384

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCACTTGATCAATAACCATG

13-283

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACTCAAACGCTTTAACCAGG

13-275

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGATCCCAAAAATACTTACGG

13-219

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTCACATCTTCAACCAGC

13-109

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGGTTCGCTTGGG

13-94

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGTTGTCCACATAGGTAACGC

94-395

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGCCTTCAATGTTGATATAGCTG

94-384

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCACTTGATCAATAACCATG
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94-283

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACTCAAACGCTTTAACCAGG

94-275
X

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGATCCCAAAAATACTTACGG

94-219

pMJ5804* pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTCACATCTTCAACCAGC

7841194

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTAGCCGTAGCCACA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCATTTTTCCTCCGGGCAG

8291194

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGGAGAGCTGGAGCCTG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCATTTTTCCTCCGGGCAG

11991731

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCGAGAGCGACGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAGTCAGATACACGATGTTCTCCT

11991578
X

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCGAGAGCGACGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTGTTGAAGCTCATCTGAAC

11991546

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCGAGAGCGACGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCGGCAGCAGAA

11991539
X

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCGAGAGCGACGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACAGGCTACGCTGACGA

13761731
X

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCAGCCAGAGCGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAGTCAGATACACGATGTTCTCCT

13761578
X

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCAGCCAGAGCGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTGTTGAAGCTCATCTGAAC

13761546
X

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCAGCCAGAGCGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCGGCAGCAGAA

13761539
X

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCAGCCAGAGCGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACAGGCTACGCTGACGA

14281731
X

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTGACGCGGATCG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAGTCAGATACACGATGTTCTCCT

14281578
X

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTGACGCGGATCG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTGTTGAAGCTCATCTGAAC

14281546
X

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTGACGCGGATCG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCGGCAGCAGAA

26

14281539
X

pDEST527 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTGACGCGGATCG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACAGGCTACGCTGACGA

C
Amino
Acid
Range

Construct Plasmid

Primers (5’-3’)

1-395

pMJ5897* pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGCCTTCAATGTTGATATAGCTG

1-384

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCACTTGATCAATAACCATG

1-283
X

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACTCAAACGCTTTAACCAGG

1-275

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGATCCCAAAAATACTTACGG

1-219

pMJ5899* pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTCACATCTTCAACCAGC

1-109

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGGTTCGCTTGGG

1-94

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGAGCTCACTGCA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGTTGTCCACATAGGTAACGC

13-395

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGCCTTCAATGTTGATATAGCTG

13-384

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCACTTGATCAATAACCATG

13-283

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACTCAAACGCTTTAACCAGG

13-275

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGATCCCAAAAATACTTACGG

13-219

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTCACATCTTCAACCAGC

13-109

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGGTTCGCTTGGG
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13-94

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCAAATGATGATCTATGCGAAATTCGA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGTTGTCCACATAGGTAACGC

94-395

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGCCTTCAATGTTGATATAGCTG

94-384

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCACTTGATCAATAACCATG

94-283

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACTCAAACGCTTTAACCAGG

94-275

pMJ5913* pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACGATCCCAAAAATACTTACGG

94-219

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGATGGCGTGCCGTC
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTCACATCTTCAACCAGC

7841194

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTAGCCGTAGCCACA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCATTTTTCCTCCGGGCAG

8291194

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGGAGAGCTGGAGCCTG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCATTTTTCCTCCGGGCAG

11991731

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCGAGAGCGACGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAGTCAGATACACGATGTTCTCCT

11991578
X

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCGAGAGCGACGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTGTTGAAGCTCATCTGAAC

11991546

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCGAGAGCGACGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCGGCAGCAGAA

11991539
X

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCGAGAGCGACGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACAGGCTACGCTGACGA

13761731
X

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCAGCCAGAGCGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAGTCAGATACACGATGTTCTCCT

13761578

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCAGCCAGAGCGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTGTTGAAGCTCATCTGAAC

13761546

pMJ5922* pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCAGCCAGAGCGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCGGCAGCAGAA

13761539
X

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGAGCAGCCAGAGCGAA
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACAGGCTACGCTGACGA
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14281731
X

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTGACGCGGATCG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAGTCAGATACACGATGTTCTCCT

14281578

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTGACGCGGATCG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGTGTTGAAGCTCATCTGAAC

14281546

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTGACGCGGATCG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCCGGCAGCAGAA

14281539
X

pDEST566 F:
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTATTTTCAGGGCATGCGTGACGCGGATCG
R:
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACAGGCTACGCTGACGA

2.2 Validation of Autoinduction Method
While not all possible constructs were used for the purpose of this study, all were to be
screened in small scale solubility testing and added into the Junop Lab Plasmid Library. As
nearly each truncation was cloned into both pDEST527 and pDEST566 expression vectors, there
were just fewer than 60 constructs to screen (some of the initial 66 had been discarded due to
persistent mutations during the PCR and cloning process). For this reason, a higher throughput
method with less consistent monitoring than traditional isopropyl β- d-1-thiogalactopyranoside
(IPTG) induction in LB was ideal. Using Studier’s autoinduction media (Table 3), E. coli were
able to self-induce plasmid expression through a progressive increase in lactose metabolization,
eliminating the need to monitor OD and allowing multiple constructs to undergo solubility
screening simultaneously55. The efficacy of induced expression using autoinduction media was
validated using a control plasmid with a known expression profile from the Junop Lab. The
control plasmid was heat shocked into 50 L BL21DE3T1R competent cells for 50s in a 42 C
water bath then placed on ice for 2mins. Cells were plated on ampicillin-LB-agar plates and left
to grow overnight at 37 C. The next morning a colony was selected and grown in 10mL
ampicillin-inoculated LB media for 16-18h at 37 C in a shaking incubator at 225rpm. 100 L of
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the culture was then diluted into 10mL of ampicillin-inoculated autoinduction media to create
secondary cultures. Multiple autoinduction cultures were made to study expression profiles from
various temperatures, and with various durations of growth. One secondary culture was also
grown using 10mL LB media with standard IPTG induction once optical density reached 0.6 to
obtain the control expression profile. This culture was grown at 37 C in a shaking incubator at
225rpm. Protein extraction was then completed using B-PER (Thermo Scientific, United States),
a chemical lysate, as per manufacture’s protocol. 15% sodium dodecyl-sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) was performed on soluble and insoluble protein fractions to
determine the time and temperature of autoinduction growth which optimized protein expression.
The same process was repeated for an RGNEF construct to validate time and temperature using
autoinduction in comparison with its LB-IPTG compart.
Table 3. Studier’s Autoinduction Media used for growth of RGNEF constructs. Following autoclave
sterilization of the base broth and cooling overnight, filter sterilized sugars and glycerol could be added to
complete the media55.
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2.3 Protein Expression and Purification
2.3.1 Small Scale Solubility Testing
To determine the plausibility of successful RGNEF construct purification in the largescale, constructs underwent small scale solubility testing. 50ng of expression plasmid stock DNA
was mixed with 50 L of BL21DE3T1R E. coli competent cells, heat shocked for 50s in a 42 C
water bath and left on ice for 2mins. Cells were then plated onto ampicillin-LB-agar plated and
incubated overnight at 37 C. Single colonies were then selected and grown in 10mL LB media
inoculated with ampicillin for 16-18h in a 37 C shaking incubator at 225rpm. 100 L of this
primary culture was then diluted into 10mL of autoinduction media inoculated with ampicillin
and grown for 4h at 37 C in a shaking incubator at 225pm, followed by 20h at 16 C. Protein was
extracted using B-PER (Thermo Scientific, United States) as per manufacture’s protocol,
providing a soluble and insoluble protein fraction. Samples from each fraction were run on 15%
polyacrylamide gel SDS-PAGE for 1h at 165V to determine degree of soluble protein recovery.
2.3.2 Large Scale Expression
Constructs selected to move to large-scale growth and purification were transformed and
grown in 10mL LB media cultures following an identical protocol to 2.3.1 Small Scale Solubility
Testing. The entirety of the primary culture was then diluted into 1L autoinduction media in a
wide-bottom 4L Erlenmeyer flask, inoculated with ampicillin. 1L cultures were grown for 4h at
37 C, followed by 20h at 16 C in a shaking incubator at 220rpm. The contents of 1L cultures
were then centrifuged for 15min at 4000rpm to harvest E. coli cells. Supernatant media was
discarded, and cells were resuspended and washed in approximately 15mL 1x phosphatebuffered saline (PBS). Cell suspensions were centrifuged for 20min at 3500rpm to recover a final
cell pellet which was immediately placed into storage at -80 C for later purification.
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2.3.3 Protein Purification
Cell pellets were thawed from -80 C storage at room temperature. The weight of thawed
pellets was measured, and pellet were resuspended in approximately 10mL/g cell pellet of filter
sterilized nickel-A running buffer (Ni-A) comprised of 800mM NaCl, 20mM Tris-HCl pH 8.0,
and 10% v/v glycerol. A mixture of 100x water soluble and ethanol soluble protease inhibitors
were added for a working concentration of 1x. Cell suspensions were then lysed by French
Pressure Cell, and protease inhibitors added to cell lysate. Cell lysates were centrifuged for
50min at 20 000rpm to separate soluble protein from insoluble protein. Fractions were separated,
insoluble protein pellets were stored at -20 C for later sampling, and soluble protein was
harvested and treated with a final volume of water-soluble protease inhibitors only.
Purification of RGNEF protein was completed by nickel-immobilized metal affinity
chromatography (Ni-IMAC) on an ÄKTA Start Protein Purification System (Cytiva Life
Sciences, United States) equipped with a 5mL HiTrap HP column (Cytiva Life Sciences, United
States). Soluble protein was injected onto the column at a rate of 0.5mL/min, followed by an
approximately 50mL wash of Ni-A at 2mL/min. Non-specific proteins were then washed from
the column at 2.0 mL/min with either an isocratic or gradient increase of filter-sterilized nickel-B
elution buffer (Ni-B) containing 800mM NaCl, 300mM imidazole, 20mM Tris-HCl pH 8.0, and
10% v/v glycerol. The selection of isocratic or gradient increase of Ni-B was dependent on
whether it was the first attempt of construct purification (typically isocratic for increased control
and monitoring) or subsequent purifications (typically gradient, requiring minimal monitoring).
Washing of the non-specific proteins would continue until a 15% v/v Ni-B/Ni-A was reached. A
static wash of approximately 50mL 15% Ni-B at 2.0mL/min was then completed. Elution was
completed at a rate of 1.0mL/min in 100%v/v Ni-B. As RGNEF constructs were designed with
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an N-terminal 6xHis-tag in both pDEST527 and pDEST566, their affinity to the column was
such that they are only out-competed by concentrations of imidazole 210mM or higher,
corresponding to 70%v/v Ni-B/Ni-A. For this reason, 100% Ni-B elution fractions were
presumed to contain RGNEF construct protein and were immediately sampled for SDS-PAGE
and stored at -80 C. Other fraction collected throughout the purification were sampled for SDSPAGE and stored at -20 C. SDS-PAGE samples were combined with 2xSDS dye with 5% BME
for a working concentration of 1x, boiled for 6min, and centrifuged at 14 000 x g for 8 min. A
15% w/v polyacrylamide gel SDS-PAGE was then run at 165V for 1h to confirm the location of
RGNEF construct protein. Chromatography data analysis during purification was done using the
UNICORN 7 software (Cytiva Life Sciences, United States).
2.3.4 Western Blot
Western blotting was performed on a select number of SDS-PAGE gels, run as described
above. Following completion of the 1h 165V electrophoresis, the Western Blot cassette
assembled in transfer buffer (25mM Tris, 190mM glycine, 20% v/v glycerol) and run for 65min
at a constant current of 225A to transfer protein onto the membrane. The transferred membrane
was then soaked in blocking buffer (Tris-buffered saline with 0.1% Tween 20 detergent (Sigma
Aldrich, Canada) (TBST) and 5% bovine serum albumin (BSA)) for 1h at room temperature. The
membrane was then soaked in TBST supplemented with primary Anti-6xHis-tag mouse
monoclonal antibody (Product # 37-2900, Invitrogen, Ontario, Canada) overnight at 4 C. The
next morning the membrane was washed three times with TBST + 3% BSA, each for 10min at
room temperature. The membrane was then incubated with TBST + 3% BSA supplemented with
goat anti-mouse IgG secondary antibody, conjugated with alkaline phosphatase (AP) (Product #
A16069, Invitrogen, Ontario, Canada). Detection of the 6xHis-tag was done visually through the
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chemiluminescence of AP following use of AP Conjugate Substrate Kit (BioRad, Ontario,
Canada) and documented via photograph.
2.3.5 Size Exclusion Chromatography
Size exclusion chromatography (SEC) was performed on the ÄKTA Start Protein
Purification System (Cytiva Life Sciences, United States) using HiPrep 16/60 Sephacryl S300HR (Cytiva Life Sciences, United States). Protein purified by Ni-IMAC was injected onto the
column at 1.0mL/min, which remained for the duration of the experiment. Fractions were
collected in 1mL volumes for easy isolation of elutants over the entirety of the experiment.

2.4 Biochemical Analysis
2.4.1 Thermal Shift Assay
As the physical characteristics of RGNEF remain uncharacterized in the literature, and
there has been significant difficulty over the years with purification of RGNEF, pH and salt
screening thermal shift assays were performed on purified constructs to determine optimal buffer
conditions for future experiments. The Durham pH Screen (Molecular Dimensions, England) and
The Durham Salt Screen (Molecular Dimensions, England) were used to analyze purified
constructs in a variety of conditions. Each screen contained 96 different solutions which could be
combined with protein to analyze their stability in various conditions. Purified protein had to be
within 1.0-1.5mg/mL for optimal plate reading. Protein was thawed on ice and 1 L/mL-protein
of SYPRO Orange Protein Stain (Thermo Scientific, United States) was added. In a 0.1mL-96well plate, 10 L of protein was combined with 10 L of screen condition. The plate was covered
with a clear, optical seal and placed in the QuantStudio5 Real-Time PCR (Applied Biosystems,
Ontario, Canada) where method temperature began at 12 C and increased at a steady rate of
0.2 C/s until 60 C was reached. Fluorescence reading from stained protein was used as a
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measure of total stable protein. As protein denatured under the various conditions at increasing
temperatures, fluorescence would increase accordingly. Thermal shift data analysis was
completed using Protein Thermal Shift Software v1.4 (Applied Biosystems, Ontario, Canada).
2.4.2 Size Exclusion Chromatography-Multiangle Light Scattering
Size exclusion chromatography-multiangle light scattering (SEC-MALS) was graciously
completed with the assistance of Megan Noble of the Stathopulos Lab (Schulich School of
Medicine and Dentistry, Western University, Canada). Purified pMJ5899 was dialyzed overnight
at 4 C into a 50mM sodium citrate tribasic-HCl pH 5.5, 300mM NaCl, 0.5mM DTT running
buffer. SEC was performed using a GE Healthcare Superdex 200 10/300 GL Increase column
(GE Healthcare, United States) and MALS performed using a HELEOS II detector system
(Wyatt Technology Corporation, United States). Equilibration of the SEC-MALS system with
running buffer ran at 0.5mL/min for at least 1 column volume or until MALS detection baseline
was less than 0.02mV, which ever took longer. Following equilibration, 100 L of purified
pMJ5899 was injected into a 100 L sample loop which began the SEC-MALS experimental
method. The experimental method occurred at a flowrate of 0.5mL/min. Light scattering data
was collected by HELEOS II and analyzed using the ASTRA software to calculate the MW of
purified pMJ5899 (Wyatt Technology Corporation, United States). Eluted SEC samples were
collected in a 96-deep-well plate and analyzed using SDS-PAGE.
2.4.3 Surface Plasmon Resonance
Surface plasmon resonance (SPR) was graciously completed by Dr. Crystal McLellan of
the Strong Lab (Robarts Research Institute, Western University, Canada) using the Reichert
2SPR, SR7500DC System (Reichert, New York, USA). Purified pMJ5899 was dialyzed into
1xPBS, diluted to 100 g/mL with 10mM NaAc-HCl pH 4.0, and immobilized onto a
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carboxymethyl dextran SPR chip via 6xHis-tag. A TDP-43 construct kindly donated by Dr.
Stanley Dunn (Shulich School of Medicine and Dentistry, Western University, Canada) was used
as experimental analyte. The TDP-43 construct ranged TDP-431-103 and was altered cysteine-free
as it was previously used for crystallographic analysis (hereon referred to as TDP-431-103CF).
Reference channel on the same chip, which did not contain immobilized purified pMJ5899, was
run in tandem with the experimental channel to produce a baseline that would allow for
quantification of purified pMJ5899/TDP-43 interaction. A running buffer of 1xNBS-PBST
(0.2% Tween, 1% BSA, 400 nM NaCl) was used throughout the experiment. Once purified
pMJ5899 was immobilized, a 1M ethanolamine wash followed by regeneration solution (1M
NaCl, 10% v/v glycerol) wash was performed to prepare the chip for the experimental method.
Reverse serial dilutions of TDP-431-103CF into 10 mM NaAc-HCl pH 4.0 were used as analyte
(1.25 M, 2.5 M, 10 M), each followed by a regeneration solution wash, 1xPBST blank wash,
and 10 mM NaAc-HCl pH 4.0 buffer wash. Degree of purified pMJ5899/ TDP-431-103CF
interaction was measured in micro-Response Units ( RIU) and data analyzed using SPR
Autolink 1.1.14-T (Reichert, United States).
2.4.4 Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assay (EMSA) was performed using purified RGNEF
protein and a 25-mer poly-U RNA probe with a 5’-6-FAM fluorescent tag (Integrated DNA
Technologies, United States). In the set of 20 L reactions, the concentration of purified RGNEF
was decreased step-wise by dilution with buffer to maintain salt and pH. 1 L of 1.0 M RNA
probe and 2 L 10xBSA were then added. Reactions were incubated on ice for 15mins and
combined with 4 L 6xDNA dye with glycerol to help samples settle to the bottom of gel wells
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during electrophoresis. Samples were then run on a 10w/v% native-PAGE gel for 70min at 100V
and imaged using the ChemiDoc MP plate reader (BioRad, United States).
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Chapter 3 - Results
3.1 Autoinduction Media Induces Protein Expression
Thirty-three construct boundaries were designed from the FL-RGNEF sequence. Each
construct was cloned into both pDEST527 and pDEST566 expression vectors; controlling for
constructs lost due to mutations during the cloning process, the total number of constructs was 73
(a total of 99 were designed, 26 were eliminated to mutation). While not all constructs were used
for the purpose of this study, all were produced in tandem and available for further studies if
needed. Subsequently, each construct underwent small-scale protein purification in tandem to
predict solubility prior to being used in a large-scale purification. Most commonly, expression of
target protein under the control of a T7lac promoter using E. coli competent cells is done by
closely monitoring the optical density of E. coli cultures in LB media and subsequent induction
of expression with the addition of IPTG. With around 60 constructs to test, a high throughput
growth protocol requiring minimal monitoring was preferable to allow for culture growth and
induced expression of multiple constructs concurrently. Studier’s Autoinduction Media was
designed for this purpose55. The recipe, which includes lower glucose and higher lactose levels
relative to LB media, promotes steady glucose-dependent growth followed by log phase lactosedependent growth, producing metabolites which induce target protein expression. Levels of
protein expression in autoinduction cultures are consistently higher than LB-IPTG cultures,
which may run the risk of overexpression and subsequent aggregation of our target protein. This
prompted a validation step to determine the proper time course of autoinduction culture growth
to obtain a similar expression level to LB-IPTG culture. To do so, a control protein from the
Junop Lab with a known LB-IPTG expression profile was grown in autoinduction media with
samples collected at various timepoints to be compared using SDS-PAGE. The duration of
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autoinduction growth best resembling the expression profile from LB-IPTG growth was then
implemented with an RGNEF construct, pMJ5897, selected as it is the largest construct from the
N-terminal region of the protein, and tested to validate expression levels in RGNEF.
SDS-PAGE of samples taken from both the IPTG-induced control protein as well as an
array of autoinduction culture growth times showed that autoinduction cultures highly induced
soluble target protein expression after sustained growth at low temperature preceded by acute
duration growth at a higher temperature. The acute duration growth at a high temperature likely
did not result in protein expression alone as E. coli were still able to utilize the small glucose
concentration within the media. However, as the doubling time for E. coli culture growth at 37C
is approximately 25 minutes, high temperature growth allowed for the creation of a highly
populous culture which was then able to induce high levels of expression during low temperature
growth. Visual quantification of SDS-PAGE bands suggested that similar levels of control
protein were seen following 4h at 37 C + 20h at 16 C.
This assay was then completed on pMJ5897 without alterations to durations of growth.
SDS-PAGE results were extremely similar to that of the control protein, showing highly induced
expression following 4h at 37 C, followed by sustained low temperature growth. The level of
protein expression following 4h at 37 C + 20h at 16 C was slightly higher than that of the IPTGinduced culture, however as we were unsure whether protein solubility would be maintained
during a large-scale growth given the difficult nature of RGNEF, it was decided to maintain the
4h at 37 C + 20h at 16 C timeline.
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B

Figure 3A-B. Validation of Autoinduction protocol between a control protein (A) and pMJ5897 (B).
IPTG-induced cultures were grown in LB until OD = 0.6, while autoinduction cultures were grown and
sampled over a period of 48h. Using B-PER chemical protein extraction (Thermo Scientific, United
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States), soluble and insoluble fractions were collected. It was decided that 4h at 37 C + 20h at 16 C gave
optimal autoinduced-expression.

3.2 Purification of N-terminal Constructs
3.2.1 Purification of pMJ5897
Construct pMJ5897 covers the largest region of the N-terminal domain of RGNEF
(amino acids 1-395), including the entirety of the predicted interacting region between RGNEF
and TDP-43. For this reason, it was selected to be the first construct for purification. pMJ5897,
being expressed in the pDEST566 vector, included a 40.2kDa 6xHis-MBP-fusion tag linked to
the 44.0kDa construct for an open reading frame (ORF) molecular weight of 87.9kDa. Following
culture growth of pMJ5897, 7g of cell pellet were harvested, resuspended in Ni-A buffer and
lysed by French Press. Soluble and insoluble lysate fractions were separated by centrifugation,
leaving approximately 60mL of soluble lysate. Soluble lysate was pumped onto a 5mL HiTrap
HP column (Cytiva Life Sciences, United States) Ni-IMAC column at 0.5mL/min at room
temperature. Inclusion of a 6xHis-MBP tag promoted strong association of the target protein
with Ni2+ charged resin beads within the column. This permitted a gradient wash of the column
from 0-15% Ni-B (0-45mM imidazole) for the removal of impurities, followed by a static 15%
Ni-B wash. Elution of pMJ5897 was performed at 100% Ni-B (300mM imidazole) which
reached a peak UV absorption of 2000mAu (the maximum reading on the AKTA Start
Purification system), plateauing for approximately 5mL before steadily decreasing over 20mL.
9.2mL of elution protein was collected during the UV peak with a concentration of 7.51mg/mL
as measured via Nanodrop. SDS-PAGE of samples taken throughout the purification process
gave visual confirmation of a strongly induced, soluble protein species running at approximately
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85kDa with an elution positively correlating with imidazole concentration; this was presumed to
be pMJ5897 (Figure 4).

Figure 4. SDS-PAGE of Ni-IMAC purification samples of pMJ5897. pMJ5897 was highly induced and
appeared at high levels during 100% Ni-B elution. The green arrow indicates location of pMJ5897.

Addition of the 6xHis-MBP fusion tag seemed to be effectively solubilized pMJ5897
during purification. This is particularly notable as the N-terminal region of RGNEF has yet to
have a described purification in the literature and is cited as being “difficult to clone, express and
purify”56. However, the preference moving forward for biophysical analysis of pMJ5897 was
removal of the fusion tag to circumvent difficulties in protein characterization which could occur
due to the large size of the fusion tag itself or flexibility of the linker region between the fusion
tag and the RGNEF construct. For this reason, 200 L of 7.51mg/mL elution protein was sampled
to undergo TEV enzymatic cleavage to remove the fusion tag from the RGNEF construct.
Protein was dialyzed overnight into 500mL of TEV Protease reaction buffer (200mM KCl,
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50mM Tris HCl pH 8.0, 0.5mM EDTA, 1mM BME). Protein concentration of the 200 L sample
remained the same following dialysis, leaving 1.5mg of protein available for the reaction. A
standard reaction ratio of 15:1 protein:TEV protease was followed, with the addition of 100 L
TEV protease (1mg/mL). The reaction was left in an Eppendorf tube for 24h at 4 C.
Subsequently, there presented no evidence of protein precipitation before or after quick
centrifugation of the reaction tube. SDS-PAGE analysis demonstrated approximately 50%
cleavage efficacy (Figure 5). Despite lower than ideal efficacy, it was decided to move forward
with a large scale TEV protease reaction due to relatively high pMJ5897 elution concentration
and volume (9.0mL at 7.51mg/mL). 5mL of pMJ5897 elution protein was buffer exchanged into
200mM KCl, 50mM Tris HCl pH 8.0, and 0.5mM EDTA using a HiPrep 26/10 Desalting
column (Cytiva Life Sciences, United States), with the recovery of 9mL at 2.00mg/mL (18mg)
collected into a 50mL falcon tube. BME was added following buffer exchange for a final
concentration of 1mM. Attempting to increase cleavage efficacy, the reaction ratio was increased
to slightly over 10:1 with the addition of 2x1mL aliquots of 1mg/mL TEV protease, and the
reaction time increased from 24h to 48h. SDS-PAGE using sampled from the large-scale reaction
displayed a similar cleavage efficacy to the small-scale test, suggesting that the remaining
uncleaved protein was inaccessible to TEV protease (Figure 5). Reverse Ni-IMAC was used to
isolate cleaved, untagged RGNEF protein from both uncleaved protein and cleaved 6xHis-MBP.
The 10mL reaction solution was buffer exchanged into Ni-A buffer and loaded onto a 5mL
HiTrap HP column (Cytiva Life Sciences, United States) a 0.5mL/min. Cleaved protein was
expected to flow through the column during the initial 100% Ni-A wash, however there was
minimal UV absorption to indicate this, peaking at 24mAu. A stepwise increase in Ni-B buffer
from 0-20% likewise displayed minimal UV absorption. Elution of remaining bound proteins at
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100% Ni-B, which would predictably include uncleaved pMJ5897 and cleaved 6xHis-MBP,
showed a sharp peak at 2000mAu which quickly receded. SDS-PAGE of samples taken through
the reverse Ni-IMAC process displayed minimal visible protein, apart from elution samples
which showed faint banding around 85kDa and 40kDa, the expected molecular weights (MWs)
of uncleaved pMJ5897 and 6xHis-MBP, respectively. To explain the disappearance of protein,
cleaved RGNEF protein and 6xHis-MBP along with uncleaved pMJ5897 may have formed
soluble aggregates due to the hydrophilicity of MBP. These soluble aggregates may have
occupied the column throughout the 100% Ni-B elution, outcompeting imidazole. Unfortunately,
this theory was not considered before the used column was stripped and recharged. Sizeexclusion chromatography was suggested to resolve cleaved RGNEF from other products in the
TEV reaction, however this idea was dismissed due to the relatively similar size of the 6xHisMBP tag (40.2kDa) and the RGNEF construct (44.0kDa). It was then decided to move forward
with the purification of a construct with a larger size differential between the protein and fusion
tag.

A

B

C
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Figure 5 A-C. (A) SDS-PAGE testing the efficacy of TEV cleavage on pMJ5897 in a small-scale test at a
15:1 ratio. TEV appears in the first lane just above 25kDa and can be seen in the subsequent lanes. 6xHisMBP (40.2kDa) appears in the second lane between 35-50kDa, but is superimposed by RGNEF1-395
(44.0kDa). Uncleaved pMJ5897 is seen in the third lane. (B) SDS-PAGE of large scale TEV cleavage
samples. (C) Attempted isolation of RGNEF1-395 using reverse Ni-IMAC following TEV reaction of
pMJ5897. Minimal to no recovery of RGNEF1-395 can be seen in the flow-through.

3.2.2 Purification of pMJ5913
Following the difficulties isolating the cleaved RGNEF protein of construct pMJ5897
from both uncleaved pMJ5897 and cleaved 6xHis-MBP, it was decided to attempt the
purification of a construct which could be better resolved based on a larger size differential from
the 6xHis-MBP tag. Construct pMJ5913 was decided as an optimal construct as it contained the
smallest predicted LeuR organized region of the N-terminus, RGNEF94-219 (Figure 6), with a
molecular weight of 17.2 kDa (excluding the 6xHis-MBP and remainder of the ORF, total ORF
molecular weight = 57.45 kDa). Following culture growth, 7g of cell pellet were harvest and
resuspended in 70mL of Ni-A buffer, lysed via French Press cell, and centrifuged to isolate
soluble and insoluble lysates. 60mL of soluble lysate was recovered and pumped onto a 5mL
HiTrap HP column (Cytiva Life Sciences, United States). Ni-IMAC column at 0.5mL/min at
room temperature. Similar to the purification of pMJ5897, a gradient wash of the column from 015% Ni-B (0-45mM imidazole) was used for the removal of impurities, followed by a static 15%
Ni-B wash. Elution of pMJ5913 was performed at 100% Ni-B (300mM imidazole) which
reached a peak UV absorption of 2000mAu (the maximum reading), plateauing for
approximately 2mL before steadily decreasing over 16mL. 15mL of elution protein at
3.574mg/mL was recovered from fractionation during the peak UV reading, totalling 53.61mg of
pMJ5913 protein. SDS-PAGE analysis of samples taken throughout the purification process
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confirmed a highly induced, soluble protein which eluted at high levels during administration of
100% Ni-B buffer and ran at approximately 55kDa, visually confirming the induction and
purification of 57.45 kDa pMJ5913 (Figure 6).

Figure 6. SDS-PAGE of Ni-IMAC purification samples of pMJ5913. pMJ5913 was highly induced and
appeared at high levels during 100% Ni-B elution. The green arrow indicates location of pMJ5913.

For later biophysical analyses of pMJ5913, removal of the 6xHis-MBP tag was preferred.
Following difficulties cleaving the fusion tag from pMJ5897, it was decided to assay varying
reaction ratios over 48h and 72h. Two 250 L samples of elution protein were dialyzed overnight
into 500mL each of 200mM KCl, 50mM Tris HCl pH 8.0, 0.5mM EDTA, 1mM BME at 4C.
Protein concentration following dialysis was 3.273 mg/mL. Two sets of four 50 L protein:TEV
conditions were created (15:1, 10:1, 8:1, 4:1, 2:1) with one set left at 4 C for 48h and one for
72h. No conditions presented any evidence of protein precipitate. SDS-PAGE analysis of
samples taken from both 48h and 72h reactions show no visible difference between the durations
46

of reaction (Figure 7) and minimal visible difference with increasing TEV protease concentration
beyond an 8:1 ratio (Figure 7).

B

A

Figure 7 A-B. (A) 48h TEV cleavage assay of pMJ5913. Increased TEV concentration did not
significantly increase the degree of pMJ5913 cleaved. (B) 72h TEV cleavage assay of pMJ5913. Similar
results were seen to that of the 48h assay, indicating that increased time did not increase cleavage
efficacy.

Similar to pMJ5897, this indicated that there remained a subpopulation of pMJ5913 that
was inaccessible to TEV protease. However, due to the larger size differential between the
6xHis-MBP and the inserted RGNEF truncation, it was possible that cleaved protein could be
isolated using SEC. It was decided to complete a large-scale TEV digest at an 8:1 ratio over 48h
at 4 C. 10mL of elution protein was buffer exchanged into 200mM KCl, 50mM Tris HCl pH 8.0,
and 0.5mM EDTA using a HiPrep 26/10 Desalting column (Cytiva Life Sciences, United States),
with the recovery of 15mL at 2.487mg/mL (37.31mg) collected into a 50mL falcon tube. BME
was added following buffer exchange for a final concentration of 1mM. TEV protease was added
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for a final ratio of 8:1 protein:TEV and left for 48h at 4C, after which there was no evidence of
precipitation. The reaction solution was injected and processed on a HiPrep 16/60 Sephacryl S300HR (Cytiva Life Sciences, United States). Unicorn software analysis displayed four distinct
peaks, with the first peak showing bidispersity and the final peak occurring after one full column
volume, typical of a salt peak. SDS-PAGE analysis of samples taken from the first bidisperse
peak show uncleaved pMJ5913 (57.45 kDa) and cleaved pMJ5913 (13.7kDa) eluting together,
suggesting that the cleaved LeuR region of RGNEF tends to associate with itself and/or the
uncleaved pMJ5913 to create soluble oligomers, high-order polymers or aggregates (Figure 8).
Samples taken from the second peak display cleaved 6xHis-MBP (40.4 kDa), and samples from
the third peak display TEV protease (27.9kDa) (Figure 8). There were no further peaks isolating
cleaved pMJ5913 protein, further corroborating the idea that monomeric pMJ5913 lacking the
fusion tag tends to associate with other monomeric units of cleaved or uncleaved pMJ5913 to
form soluble oligomer, high-order polymers, or soluble aggregate.

A
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B
Figure 8 A-B. Attempted isolation of RGNEF94-219 using SEC. Chromatograph is displayed in (A). Samples
from peak 1 were mainly comprised of uncleaved pMJ5913, with a small amount of RGNEF94-219 (13.9kDa)
seen between 11 and 17kDa. Peak 2 displayed cleaved 6xHis-MBP tag (40.2kDa), and peak 3 displayed
TEV protease (27.9kDa) (B).

3.2.3 Purification of pMJ5804
Due to the persistently low TEV cleavage efficacy and difficulty isolating cleaved
RGNEF protein when purifying constructs expressed in pDEST566, it was decided to express
and purify a pDEST527 construct. While the RGNEF94-219 construct expressed in pDEST527
(pMJ5804) was relatively less soluble than in pDEST566 (pMJ5913), the use of the pDEST527
expression plasmid mitigated removal of the 6xHis-MBP tag following purification. Despite the
lower solubility, it was hoped that growth of a large-scale culture would result in the recovery of
sufficient untagged protein to perform downstream biophysical analyses. The ORF molecular
weight of pMJ5804 was 17.2kDa.
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Following culture growth, 7g of cell pellet were harvested and resuspended in 70mL of
Ni-A buffer, lysed via French Press cell, and centrifuged to isolate soluble and insoluble lysates.
60mL of soluble lysate was recovered and pumped onto a 5mL HiTrap HP column (Cytiva Life
Sciences, United States) Ni-IMAC column at 0.5mL/min at room temperature. Unlike previous
purifications, a 5% isocratic increase in Ni-B buffer used performed up to 15% Ni-B (45mM
imidazole) to isolate the concentration of imidazole more accurately at which different products
eluted. A static 15% Ni-B wash was performed followed by a final elution at 100% Ni-B
(300mM imidazole). Peak UV absorption during the 100% Ni-B elution reached 280mAu,
significantly less than elution UV readings from previous purifications. 15mL of 100% elution
protein was collected with a concentration of 0.593 mg/mL. SDS-PAGE analysis of samples
taken throughout the purification process display no distinct single band characteristic of induced
protein expression (Figure 9A). Western Blot was performed on the SDS-PAGE gel, using
primary anti-His and secondary His-anti-alkaline phosphatase antibodies revealing possibly three
separate populations of pMJ5804: monomeric (17.2kDa), trimeric (51.6kDa), and tetrameric
(68.8kDa) (Figure 9A). To confirm this was the protein of interest, a second SDS-PAGE and
Western Blot analysis was performed comparing uninduced lysates and induced lysates (Figure
9B). Western Blot revealed proper induction of pMJ5804, though only at a molecular weight
corresponding to monomeric protein in both soluble and insoluble fractions (Figure 9B). This
suggested that the different pMJ5804 species formed at some point during the purification
process.
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B
Figure 9 A-B. SDS-PAGE and Western Blot of Ni-IMAC purification samples of pMJ5804. pMJ5804
was induced at low levels, appearing in three species during 100% Ni-B elution. The green arrow
indicates the expected location of monomeric pMJ5804, while the blue arrow indicates trimeric pMJ5804,
and the orange arrow tetrameric pMJ5804.
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The distinct and disperse molecular weights of each species suggested that they may be
able to be separated using SEC. 4mL of elution protein was injected onto HiPrep 16/60
Sephracryl S-300HR (Cytiva Life Sciences, United States) equilibrated with 500mM NaCl,
20mM Tris HCl pH 8.0 at 1.0mL/min. UV analysis throughout the SEC displayed two
polydisperse peaks with consistently low mAu reading, indicating poor resolution of the sample.
Most likely this was due to low sample concentration. SDS-PAGE analysis of samples taken
during chromatography showed that the larger pMJ5804 species, including predicted trimer and
tetramer, were eluted throughout the SEC process indicating that they may be forming soluble
aggregates (Figure 10). Monomeric pMJ5804 was present in the 100% elution but did not appear
on the SDS-PAGE gel. As such, a second purification with a larger 2L culture to obtain a higher
100% elution yield and alleviate the poor resolution during SEC was executed.

Figure 10. SDS-PAGE of samples taken from SEC of pMJ5813 attempting to separate monomeric (green
arrow), trimeric (blue arrow), and tetrameric (orange arrow) species. All pMJ5813 species appeared to
elute together in peak 1, suggesting the formation of soluble aggregates.
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A 2L culture of pMJ5804 was then grown and cells harvested. 13g of cell pellet were
resuspended in 130mL of Ni-A and lysed via French Press cell. 130mL of soluble lysate was
recovered and pumped onto a 5mL HiTrap HP column (Cytiva Life Sciences, United States) at
0.5mL/min at room temperature. A 5% isocratic increase in Ni-B buffer was used up to 15% NiB (45mM imidazole). A static 15% Ni-B wash was performed followed by a 70% Ni-B wash to
try and flush out less tightly bound pMJ5804 species and obtain a more homogenous 100%
elution. Peak UV reading reached ~500mAu during the 70% wash. A final elution at 100% Ni-B
(300mM imidazole) was performed, displaying a shorter and broader UV peak of ~150mAu.
10mL of 70% wash protein was collected with a concentration of 0.472 mg/mL. 30mL of 100%
elution protein was collected at a concentration of 0.199mg/mL. SDS-PAGE analysis of samples
taken from the purification process display a greater heterogeneous population from the 70%
wash, compared to a more homogenous population within the 100% elution of a protein species
with MW corresponding to trimeric pMJ5804 (Figure 11A). However, protein eluted during the
100% elution was less than half the concentration of the 70% wash protein and less visible on the
SDS-PAGE gel. Western Blot was then performed on samples taken during purification to
confirm the identity of elutants. Visual analysis of the Western Blot confirmed a much more
heterogenous mixture of 6xHis-tagged protein within the 70% wash. Most likely, the strongly
stained bands were species of pMJ5804 in transient oligomeric states, again corroborating
previous results indicating that RGNEF LeuR constructs tend to self-associate and are not stable
monomers in solution (Figure 11B). Visual analysis of the 100% elution samples showed a weak
presence of trimeric and tetrameric pMJ5804, though at minimal concentrations (Figure 11B). A
strong band also occurred at 25kDa, which did not correspond to the MW of pMJ5804 nor any of
its oligomeric states. A strong band at this MW also eluted early in the second purification
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(Figure 11A), as well as in other purifications done in the lab. The strength of this band could
likely be attributed to the relatively larger culture size (2L). For these reasons, it was determined
that this band was just a cellular contaminant. Due to the heterogeneity and difficulty obtaining
workable concentrations of single species of pMJ5804, we moved to purify a new construct in
pDEST566.

A

B

Figure 11 A-B. Purification of 2L cultured pMJ5804 (A) and Western Blot (B). Tetrameric (orange
arrow) and trimeric (blue arrow) could be readily seen in the SDS-PAGE gel (A), however monomeric
pMJ5804 was more elusive. All three could be identified in the Western Blot (B). The heterogenous
nature and low purification concentration prompted dismissal of pMJ5804.

3.2.4 Purification of pMJ5899
Results from the purification of pMJ5804 suggested that the absence of the 6xHis-MBP
fusion tag allowed N-terminal RGNEF to self-associate and form different oligomeric species.
The presence of the fusion tag seemed to prevent this during earlier purifications of pMJ5897
and pMJ5913. Considering this, it was decided to purify pMJ5899 (74.59kDa) which contained
RGNEF1-275 (30.3kDa) and the 6xHis-MBP tag (40.2kDa). This construct specifically showed
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high solubility during initial screening and truncations with similar domains were often used in
RGNEF functional studies to analyze the role of the N-terminal domain in vivo51.Additionally,
RGNEF1-275 was small enough to be differentiated from the fusion tag should TEV cleavage be
successful.
A 1L culture of pMJ5899 was grown and 5g of cell pellet were harvest and resuspended
in 50mL of Ni-A buffer and lysed via French Press cell. During lysis, a mechanical dysfunction
in the French Press cell caused entry of air into the cell and frothing of ~20mL of cell lysate
before the entire sample was visibly lysed. The cell lysate was mixed with an additional 30mL of
Ni-A buffer for a total volume of 80mL to help maintain protein solubility and centrifuged to
isolate soluble and insoluble lysates. 65mL of soluble lysate was recovered and pumped onto a
5mL HiTrap HP column (Cytiva Life Sciences, United States) at 0.5mL/min at room
temperature. A gradient wash of the column from 0-15% Ni-B (0-45mM imidazole) was used for
the removal of impurities, followed by a static 15% Ni-B wash. Elution of pMJ5899 was
performed at 100% Ni-B (300mM imidazole) which reached a sharp peak UV absorption of
1600mAu (the maximum reading), decreasing rapidly. The sharp peak and rapid decline were
most likely due to decreased cell lysis and protein recovery during French Press cell lysis. A total
of 15mL of elution protein was recovered. The first 6mL of protein had a concentration of
0.33mg/mL and final 9 mL a concentration of 0.99mg/mL. SDS-PAGE analysis of samples taken
throughout the purification process confirmed a highly induced, soluble protein which eluted at
high levels during administration of 100% Ni-B buffer and ran at approximately 75kDa, visually
confirming the induction and purification of 74.59 kDa pMJ5899 (Figure 12). A 4mL samples of
0.99mg/mL protein was taken and concentrated using a Slide-A-Lyzer MINI Dialysis Units 30
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000 MWCO centrifugation concentrator (Thermo Scientific, United States) to 2mL at
2.05mg/mL.

Figure 12. SDS-PAGE of Ni-IMAC purification samples of pMJ5899. pMJ5899 was highly induced and
appeared at high levels during 100% Ni-B elution. The green arrow indicates location of pMJ5899.

For further biophysical analysis, it was hoped removal of the fusion tag would be
possible. Eluted pMJ5899 was buffer exchanged into 200mM KCl, 50mM Tris HCl pH 8.0, and
0.5mM EDTA using a HiPrep 26/10 Desalting column (Cytiva Life Sciences, United States), and
recovered 15mL at a concentration of 0.6mg/mL. BME was added following buffer exchange for
a final concentration of 1mM. Similar to the TEV assay performed on pMJ5913, five different
reaction conditions (15:1, 10:1, 8:1, 4:1, 2:1) of 50 L were set up and left for two different time
periods of 24h and 48h at 4 C. This was shorter than the previous TEV reaction assay for
pMJ5913, which incubated for 48h and 72h, as there was minimal visible difference in reaction
efficacy between the two durations. SDS-PAGE analysis of samples taken from each condition
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display approximately 50% cleavage efficacy across all conditions, with no visible correlation
between TEV concentration and cleavage efficacy and a slight visible increase in efficacy when
left for 48h as opposed to 24h (Figure 13A-B). This influenced the decision to move forward
with a large scale TEV reaction at a 15:1 protein:TEV protease ratio for 48h, followed by reverse
Ni-IMAC to isolate RGNEF1-275. 11.5mL of 0.6mg/mL pMJ5899 previously buffer exchanged
was incubated with a 15:1 TEV concentration at 4 C for 48h. The reaction was then buffer
exchanged using the HiPrep 26/10 Desalting column (Cytiva Life Sciences, United States) into
Ni-A buffer, recovering 14.5mL of 0.4mg/mL protein. Reverse Ni-IMAC was performed using a
5mL HiTrap HP column (Cytiva Life Sciences, United States) with a gradient increase from 0100% Ni-B buffer (0-300mM imidazole). Properly cleaved RGNEF1-275 from pMJ5899 would
lack the 6xHis-MBP tag required for binding to resin beads, thus would elute from the column
during the flow-through stage at 0% Ni-B, resulting in an increase in UV absorption. This
increase in UV absorption was not seen during the flow-through step, indicating a lack of
cleaved protein. SDS-PAGE analysis of samples taken during reverse Ni-IMAC confirms this
with no banding at the MW corresponding to RGNEF1-275 (30.3kDa) in the flow-through (Figure
13C). Progressing through the purification, samples display heterogenous mixtures of cleaved
fusion tag, cleaved RGNEF, and a large proportion of uncleaved pMJ5899 towards 100% Ni-B
(Figure 13C).

57

A

B

C
Figure 13 A-C. (A) 24h TEV cleavage assay of pMJ5899. Increased TEV concentration did not
significantly increase the degree of pMJ5899 cleaved. (B) 48h TEV cleavage assay of pMJ5899. Similar
results were seen to that of the 48h assay, indicating that increased time did not increase cleavage
efficacy. (C) A large-scale TEV reaction was set at a 15:1 ratio for 48h and subject to reverse Ni-IMAC to
isolate RGNEF1-275 (red arrow) from uncleaved pMJ5899 (green arrow), TEV (orange arrow) and 6xHis-
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MBP (blue arrow). RGNEF1-275 was not recovered in visible amounts in the flow-through, but did elute
with uncleaved pMJ5899 at higher % Ni-B.

3.3 Biophysical Characteristics of pMJ5899
3.3.1 Thermal Shift of pMJ5899
Considering the multiple attempts made with various constructs and techniques to isolate
cleaved RGNEF from the 6xHis-MBP fusion tag, biophysical analyses had to then be conducted
in the presence of the tag without any attempted TEV proteolysis. A protocol for purification of
RGNEF has not yet been described in the literature, notably due to persistent difficulties
solubilizing the protein; use of the fusion tag allowed us to circumvent this issue. Additionally,
an increasing number of proteins have been detailed on databases such as the Protein Data Bank
(PDB) in the presence of fusion tags, influencing our decision to keep the tag on throughout
analyses. pMJ5899 was chosen to for biophysical analysis due to its relative purity during NiIMAC purification, stability in different buffer solutions during previous work, broad coverage
of the predicted LeuR domain and similarity to constructs used in recent functional studies51.
Biophysical analysis of this construct could then help validate previous investigative work on
RGNEF and help direct future work. To determine conditions for optimal protein stability, two
PCR thermal shift screens with 96 conditions each (Durham pH Screen (Molecular Dimensions,
England) and Durham Salt Screen (Molecular Dimensions, England)) were performed. Results
from this screen guided buffer selection for subsequent SEC-MALS.
1mL of purified pMJ5899 (1.3mg/mL) in 100% Ni-B buffer was thawed on ice and 1 L
of SYPRO Orange Protein Stain (Thermo Scientific, United States) added. In a 0.1-96-well plate
10 L of protein was combined with 10uL of each screen condition. The plate was covered with a
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clear, optical seal and placed in the QuanStudio5 Real-Time PCR (Applied Biosystems, Ontario,
Canada) where method temperature began at 12 C and increased at a steady rate of 0.2 C/s until
60 C was reached. Fluorescence reading from stained protein was used as a measure of total
stable protein. More stable protein would be able to maintain a higher level of fluorescence at
higher temperatures, while less stable protein would denature causing a decrease in fluorescence.
Results from the salt screen display a clear preference of pMJ5899 for ammonium sulfate (green
circle, Figure 14A), sodium malonate (blue Asterix, Figure 14A), sodium sulfate (gold diamond,
Figure 14A), magnesium chloride (grey dash, Figure 14A), and sodium citrate tribasic (gold X,
Figure 14A). In the presence of each of these salts, pJM5899 displayed high levels of stability
across a range of ionic strengths. Results from the pH screen show the highest levels of pMJ5899
stability in pH range 5.0-6.0, particularly in the presence of citrate (blue X, Figure 14B), succinic
acid (yellow diamond, Figure 14B), and malonic acid (grey triangle, Figure 14B). With the
combined information of the two thermal shift screens, it was decided to use a buffer of 50mM
sodium citrate tribasic-HCl pH 5.5, 300mM NaCl, 0.5mM DTT as the running buffer during
SEC-MALS.
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Figure 14 A-B. Thermal shift data of pMJ5899 from the Durham Salt Screen (A) (Molecular
Dimensions, England) and the Durham pH screen (B) (Molecular Dimensions, England).

3.3.2 SEC-MALS of pMJ5899
To gain insight into the biophysical characteristics of pJM5899, particularly following the
difficulties isolating individual species of LeuR constructs from other purification by-products,
SEC-MALS was performed. 100 L of pMJ5899 was injected onto a size exclusion column and
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fractions subjected to MALS analysis. Initial chromatographic data from SEC appeared to show
protein eluate beginning towards the end of the column void volume. This was particularly
interesting as pMJ5899 has a monomeric MW of 74.59kDa, and the resolution of this column
had a resolution up to 600kDa. The chromatographic data was corroborated by MALS data,
which showed high levels of UV absorption in these initial fractions coinciding with and
immediately following the void volume (Figure 15A), as well as SDS-PAGE analysis of SEC
samples which showed pMJ5899 did in fact elute with and just after the void volume (Figure
15B). Together, these suggested the pMJ5899 was forming some sort of oligomeric quaternary
structure, or simply associating into high MW soluble aggregates. In either scenario, the structure
would be larger than what could be resolved with the column used. To try and gather more
information, MALS data was used to calculate a theoretical MW of pMJ5899 using UV
absorption data and the molecular extinction coefficient (pMJ5899 = 1.409(mg/ml)-1cm-1). Based
on these, the calculated MW of pMJ5899 was 4.586 x 106 g/mol. The evident inaccuracy of this
calculation is most likely due to the poor resolution of pMJ5899 as it eluted so close to the void
volume, but again did suggest the presence of a higher order structure.

A
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Figure 15 A-B. (A) MALS data displayed a large peak in UV (red line) absorption approximately 910mL into the SEC-MALS experiment, corresponding with the end of the column void volume. The
presence of pMJ5899 (green arrow) in these elution fractions was confirmed via SDS-PAGE (B), both
suggesting that pMJ5899 formed a higher-order structure or soluble aggregate.

3.4 Determining Region of Interaction Between TDP-43 and RGNEF
SPR analysis was conducted by immobilization of pMJ5899 and use of TDP-431-103CF as
analyte. Reverse serial dilutions of TDP-431-103CF were used to determine the degree of
interaction between the two proteins. As analyte binds to the immobilized ligand, an increase in
RIU is seen in the experimental chip channel, but not in the reference channel, indicating
increased occupancy on the chip. The strength of the interaction can be quantified by the
difference between pre-analyte injection RIU and post-analyte injection RIU. Regeneration
solution is then washed over the chip to remove any analyte, allowing for the next condition to
be injected. If an interaction occurs, it is expected there will be a concentration dependent
increase in RIU as more analyte binds to the immobilized ligand. Analysis of SPR data, done
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courtesy of Dr. Crystal McLellan, showed a significant increase in RIU (~7000 RIU)
following injection of pMJ5899 over the experimental channel, indicating pMJ5899 had
successfully bound the chip (Figure 16). As expected, this increase was not seen in the reference
channel since no pMJ5899 was injected over it. Experimental data did not display a positive
change in RIU reading during either the 1.25 M, 2.5 M, or 10 M injections of TDP-431-103CF
over the experimental channel with immobilized pMJ5899 (Figure 16). As expected, there were
no significant changes in RIU readings during analyte injection over the reference channel.
Taken together, these results suggested that pMJ5899 did associate properly with the
carboxymethyl dextran via 6xHis-MBP tag, but did not interact with TDP-431-103CF.

Figure 16. SPR data analyzing the interaction between pMJ5899 and TDP-431-103CF. Reference channel is
represented by the red line, and the experimental channel by the blue line. Injection of TDP-431-103CF in a
concentration dependent manner did not cause any visibly changes in RIU, indicating that it did not bind
pMJ5899.
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3.5 Purification of C-terminal pMJ5922
pMJ5922 was chosen as the first attempted purification of C-terminal domains,
specifically including a region of the predicted RNA-binding domain within RGNEF1428-1546.
pMJ5922 was expressed using pDEST566, thereby having a 6xHis-MBP tag, and a total MW of
58.6kDa (RGNEF1428-1546 = 14.5kDa). A 1L culture of pMJ5899 was grown and 7g of cell pellet
were harvest. During initial solubility screening, this construct appeared highly soluble
prompting a division of the cell pellet to avoid supersaturation and precipitation of pMJ5922. 1/3
of the cell pellet was isolated and resuspended in 40mL of Ni-A buffer and lysed via cell
disruptor. The following purification technique varied slightly from previous purifications as this
construct was purified by Junop Lab technician, Kun Zhang. Cell lysate was centrifuged to
isolate soluble and insoluble fractions. 40mL of soluble lysate was recovered and pumped onto a
5mL HiTrap HP column (Cytiva Life Sciences, United States) at 1.0mL/min in a 4 C cold room.
A 5% isocratic increase in Ni-B buffer from 0-15% Ni-B (0-45mM imidazole) wash used to
wash out contaminants. A static 15% Ni-B wash was performed followed by a final elution at
70% Ni-B (210mM imidazole). Peak UV absorption during the 70% Ni-B elution reached
2000mAu. 11mL of eluted protein was collected which precipitated out of solution shortly after,
most likely due to the extremely high solubility of this construct. The 11mL of protein was
centrifuged to recover any remaining soluble protein and concentrated, resulting in 4mL of
purified pMJ5922 at 1.0mg/mL. SDS-PAGE analysis of samples taken throughout the
purification process confirmed a highly induced protein which eluted at high levels during
administration of 70% Ni-B buffer and ran just above 50kDa, visually confirming the induction
and purification of 58.6kDa pMJ922 (Figure 17).
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Figure 17. SDS-PAGE of Ni-IMAC purification samples of pMJ5922. pMJ5922 was highly induced and
appeared at high levels during 100% Ni-B elution. The green arrow indicates location of pMJ5922.

3.6 Biophysical Characteristics of pMJ5922
Following successful purification of pMJ5922, thermal shift data was gathered to both
inform on the biochemical preferences of pMJ5922 and influence buffer solution selection in
future research. Like pMJ5899, both the Durham pH Screen (Molecular Dimensions, England)
and Durham Salt Screen (Molecular Dimensions, England) were used on pMJ5922 with
experimental procedure and measurements performed by QuantStudio5 Real-Time PCR
(Applied Biosystems, Ontario, Canada). 1mL of pMJ5922 (1.0mg/mL) in 100% Ni-B was
thawed on ice and mixed with 1 L of SYPRO Orange Protein Stain (Thermo Scientific, United
States). 10 L of stained protein and 10 L of screen condition were mixed in a well of a 0.1mL96 well PCR plate and covered with a clear, optical seal. The 96-well plate was placed into the
qPCR which ran a method beginning at 12 C and increased steadily at a rate of 0.2 C/s until
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reaching 60 C. Fluorescence measurements were taken throughout as an indicator of protein
stability. Results from the pH screen display a preference of approximately pH 6.0-7.0 with the
use of PIPES (light green circle, Figure 18), MES (yellow X, Figure 18), ACES (gold X, Figure
18), and Bis-Tris (orange dash, Figure 18). A salt screen was completed as well, however results
were inconclusive and appeared to show that pMJ5922 precipitated at contact with each solution.
This screen should be repeated in the near future to determine whether the inconclusive results
were due to human error or high protein instability. With the results of both screens taken into
consideration, alteration of lysis and running buffers may mitigate difficulties with precipitation
and increase protein yield during future purifications.

Figure 18. Thermal shift data of pMJ5922 from the Durham pH screen (B) (Molecular Dimensions,
England).

3.7 Defining RNA Binding Ability of pMJ5922
In order to determine whether the purified RGNEF construct pMJ5922 maintained the
RNA binding ability characteristic of its domain, an EMSA was run. Purified pMJ5922
(1.0mg/mL) in 100% Ni-B was thawed on ice and divided into five separate reaction conditions
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of decreasing molarity. Based on the volume of a 20 L reaction, the maximum molarity of
pMJ5922 was 14.45 M (condition 1), followed by 10 M, 5 M, 2.5 M, 1.25 M. BSA and
fluorescent RNA probe were added; any residual volume was filled by a solution of 800mM
NaCl, 20mM Tris-HCl pH 8.0 to maintain salt and pH across all conditions. Reactions were
incubated on ice for 15 minutes and run on a 10% native PAGE (Figure 19). Analysis of the gel
showed a concentration dependent increase in RNA binding. At 1.25 M and 2.5 M a visibly
higher amount of protein and RNA had migrated to the bottom of the gel with a small amount of
shifted protein/RNA complex towards the middle of the gel (Figure 19). At 10 M and 14.45 M
there was both a decrease in banding at the bottom of the gel and an increase in the density of
shifted protein/RNA complex, which occurred closer to running wells indicated a concentration
dependent increase in complex size (Figure 19).
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Figure 19. 10% native-PAGE of pMJ5922 EMSA. Green arrows point to shifted bands, which increase in
size in a concentration dependent manner, indicating purified pMJ5922 does bind RNA.
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Chapter 4 – Discussion
4.1 Predictive Tools Aid in the Purification of Difficult Proteins
Prior to this research, RGNEF had been touted as a particularly problematic protein to
work with due to difficulties cloning, expressing, and purifying it. To date, there had not been a
published protocol detailing successful purification of FL-RGNEF nor any truncated constructs.
With this in mind, we believed the most likely way to be able to purify any part of RGNEF
would be to first run it through a structure prediction tool and homology modeller. By doing so,
we were able to “analyze” protein structure without having to first purify the protein. Phyre2, an
online software used for structure prediction and homology modelling, was able to analyze the
sequence of FL-RGNEF and predict the probability of a given amino acid populating an
organized or disorganized region of the protein, allowing us to design construct boundaries
selectively excluding regions predicted to be highly disorganized54. Additionally, the homology
modelling feature allowed us to compare the sequence of FL-RGNEF to that of other similar
proteins and analyze their domain boundaries to influence that of our constructs. This proved to
be quite useful, as in this study we were able to successfully purify five RGNEF constructs, with
four distinct domain boundaries. In fact, the power of this software is highly utilized in structural
biology literature, having been cited 2,959 times since its publication in 2015 as of August 22,
2021.
In the last year, a new online software has become available with even stronger predictive
measures for protein structure, called AlphaFold57. More recently, an updated AlphaFold2 was
released58. Using AI technology, AlphaFold combines the thermodynamics of physical
interaction and homology modelling within a trained neural network to create a highly accurate
predictive tool58. Not only does this technology validate our method of using structure prediction
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to influence construct boundaries when cloning, expressing, and purifying select domains or
regions of a protein, it also assists with the bottleneck of structural biology58. Researchers may
no longer need to spend months or years attempting to purify and crystallize or use spectroscopic
techniques on numerous variations of similar protein constructs to determine domain structure
and implications for biological interactions. By providing researchers with a strong predictive
tool like AlphaFold, protein structure can be analyzed prior to cloning, expression, and
purification, allowing researchers to determine their area of interest for a given biological
interaction. Additionally, access to visual models of tertiary protein structure will assist
researchers in predicting the hydrophilicity or hydrophobicity of a given protein region based on
location in the FL structure, providing the opportunity to adjust construct boundaries, cloning
method, or expression method as needed. The implications for this technology are wide reaching
– pathway elucidation, disease mechanism, and pharmaceutical targeting, to name very few, may
all benefit from tools such as AlphaFold. While this technology does not entirely replace the
need for benchtop lab work, it does assist with and help streamline the process, allowing
benchtop protein purification and structural characterization to become a form of real-life
validation for AI technology.

4.2 RGNEF LeuR Tends to Form Quaternary Structures
A significant portion of time in this study was spent trying to isolate a single, untagged
species of RGNEF LeuR. Those constructs which were expressed using pDEST566 underwent
TEV proteolysis and subsequent chromatographic techniques (SEC, reverse Ni-IMAC)
attempting to isolate cleaved RGNEF protein from uncleaved protein and cleavage by-products.
pMJ5804, the only construct purified which was expressed using pDEST527, underwent SEC to
isolate a single species from the various RGNEF oligomers (monomer, trimer, tetramer). In the
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process, it was shown that TEV cleavage of LeuR constructs was relatively ineffective. TEV is
often touted as a highly effective protease with the ability to be purified in large quantities,
function in a broad range of environments, and has a selective cleavage sequence
(ENLYFQ/G)59. However, across four different RGNEF constructs, the visual efficacy of TEV
proteolysis never surpassed 50%, even at concentrations which were much higher than the
standard 15:1 ratio. Approximately 50% of purified RGNEF construct remained in a population
of uncleaved, lending to two more likely scenarios: 1) the large 6xHis-MBP tag was precluding
TEV from accessing the cleavage site, or 2) purified RGNEF constructs were forming soluble
higher-order structures, precluding TEV from accessing the cleavage site.
Possibility 1 could effectively be ruled out as the dual 6xHis-MBP fusion tag is often
used in place of the single 6xHis-tag for less soluble proteins; while the cleavage efficacy of
TEV protease on the dual 6xHis-MBP tag is slightly lower than on the single 6xHis-tag, TEV
protease is able to process ~90% of a given tagged protein population60. Possibility 2, that
purified RGNEF constructs were forming higher-order structures and obstructing the TEV
cleavage site, was corroborated by findings during the purification of pMJ5804 and SEC-MALS
data of pMJ5899. Plasmid pMJ5804 was the only construct to be purified without the dual
6xHis-MBP tag, rather using the single 6xHis-tag. As previously mentioned, the benefit of using
the dual tag is the capacity of MBP to pull an otherwise insoluble protein into solution. However,
the large MW of MBP can cause issues with downstream structure analysis, prompting many to
remove the tag with TEV protease. In the case of pMJ5804, the absence of MBP allowed us to
examine the behaviour of RGNEF94-219 in solution without the influence of a large, solubility
inducing tag. SDS-PAGE analysis of eluate protein showed no distinct, strongly induced band
that is typically characteristic, prompting anti-6xHis-AP Western Blot of the gel. Visual analysis
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of the blot using AP displayed 6xHis-tagged protein at MW corresponding to that of a pMJ5804
monomer, trimer, and tetramer, thought the amount of tagged monomer was quite low. A second
SDS-PAGE gel was run using whole-cell lysate samples which had been centrifuged to separate
soluble and insoluble fractions; following Western Blot, both samples displayed only tagged
protein at the MW of a pMJ5804 monomer. This can be rationalized by considering the relative
concentrations of pMJ5804 prior to and following Ni-IMAC purification. A relatively low
concentration of pMJ5804 is present within the entire soluble lysate fraction, but following
binding of pMJ5804 within the Ni column and elution, there is a relatively higher concentration.
This increase, along with the known instability of RGNEF, encouraged previously monomeric
pMJ5804 to associate and form the larger complexes seen in the Ni-IMAC Western Blot. The
same could be said for pMJ5897, 5913, and 5899, pushing them to form higher-order soluble
aggregates once purified, preventing TEV cleavage, but appearing as monomers in SDS-PAGE
following the addition of SDS dye with 5% BME and boiling. This theory of soluble aggregate
formation was further corroborated with SEC-MALS analysis of pMJ5899. Elution of pMJ5899
during SEC-MALS occurred immediately following the void volume of the SEC column, which
had a resolution up to 660kDa, significantly larger than 74.59kDa pMJ5899.
With the introduction of AlphaFold, we were able to analyze the structure of RGNEF
virtually to determine the plausibility of oligomerization (entry Q8N1W1)58. Expected position
error of a given residue along RGNEF1-275 was almost entirely scored as “confident” (90 >
AlphaFold confidence > 70) or “very high” (AlphaFold confidence > 90). Residues 1-94 were
predicted to be comprised of a seven-strand beta-sheet which transitioned into alpha-helices from
residues 95-219. Residues 229-254 occupy a triple-strand beta-sheet, followed by a small alpha
helix from residues 261-284. Residues 285-395 were classified as low confidence and appears to
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occupy a disorganized loop along the exterior of the protein. Given the highly organized
structure of the predicted LeuR domain, and the density of Leu residues, it is very much
plausible that purification fostered quaternary structure associations. This is particularly notable
in the region of RGNEF94-219 which may have created coiled coils (24% Leu). A similar theory
has been proposed by Kunijthapatham et al.61 who suggested that “intrinsically stable alphahelices can associate into aggregates with only coarse coiled-coil symmetry” and may present a
mechanism for pathogenic protein aggregation, such as in ALS.

4.3 Purified pMJ5899 Does Not Bind TDP-43 in vitro
SPR experiment data shown no direct interaction between pMJ5899, which encompassed
a large portion of the LeuR domain predicted to interact with TDP-43, and TDP-431-103CF.
However, previous research has pointed to a direct interaction between the two proteins via
colocalization and coimmunoprecipitation53. There are some possible explanations for the
divergent findings. One possibility is that the interaction between RGNEF and TDP-43 requires
the presence of at least one other biological molecule in order to form an indirect interaction that
leads to the recruitment of RGNEF to TDP-43+ NCIs. Currently, there is no evidence published
to suggest this, however, there is also none which refutes it.
A second reason as to why we did not observe an interaction between pMJ5899 and
TDP-431-103CF could be the structure of RGNEF itself. As described above, NI-IMAC, SEC, and
SEC-MALS data all demonstrated that LeuR RGNEF tends to form oligomeric quaternary
structures when purified due to high structural organization (predicted by AlphaFold). Though
pMJ5899 appeared to be monomeric during SDS-PAGE analysis, leading us to believe it was
monomeric for the use of SPR, observation of pMJ5899 at monomeric MW may have been due
to the addition of SDS-dye + 5% BME and subsequent boiling. Organization of pMJ5899 into
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higher order structures may have then precluded the binding site for TDP-431-103CF. For this
reason, a native-PAGE should be run in the near future to determine whether purified pMJ5899
exists as a monomer in solution.
The binding of TDP-431-103CF to RGNEF may also be dependent on the presence of
additional regions of either protein. Particularly in the case of RGNEF, a set of three parallel
alpha helices spanning RGNEF1200-1411 (as predicted by AlphaFold) run just above the organized
LeuR predicted domain. Additionally, there is large alpha helix spanning RGNEF1430-1529 which
runs directly behind and on either side of the LeuR. The ability of the LeuR region to bind TDP43 may hinge on the presence of either of these structures. The necessary structures for binding
RGNEF may also not be encompassed in the TDP-431-103CF construct. Purification of FL-TDP-43
is a lengthy process, requiring refolding of the protein following purification or mutation of
tryptophan residues to alanine, but may be required in order to observe this interaction62,63.
Related, the TDP-431-103CF was a cysteine-free construct previously used optimized for
purification and crystallization, however cysteine residues have a large influence on protein
structure and their presence may be necessary for proper conformation for RGNEF binding.

4.4 Purified pMJ5922 Retains Moderate RNA-Binding Capacity
The predicted RBD of RGNEF has previously been shown to exercise binding of target
RNA in vivo through use of split ubiquitin systems54. In this study, EMSA was used to determine
whether a truncation of the RBD, pMJ5922, would continue to bind RNA ex-vivo following
purification. Given the presence of the 6xHis-MBP tag on pMJ5922 as well as the small size of
the inserted RGNEF construct (amino acids 1428-1546), it would not have been surprising if
there had not been evident RNA binding. However, EMSA results demonstrated that pMJ5922
does in fact bind a 5’-6-FAM poly-U RNA probe in a concentration dependent manner,
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validating that the RBD can be successfully purified and maintain its domain function without
the presence of the remainder of the RGNEF protein. Yet, the degree of RNA binding in the
EMSA experiment was visibly low – less than half of the fluorescent probe bound pMJ922 in
even the highest protein concentration condition (14.45 M). This could have been due to the
high levels of salt present in the reaction. pMJ5922 proved fairly unstable in solution following
protein purification when a large amount of eluate precipitated shortly after collection. This
occurred again during latter lab work when attempting to dialyze pMJ5922 out of 100% Ni-B
and into a new buffer. For this reason, we chose to continue the EMSA experiment without
altering the storage buffer of pMJ5922 but with the consideration that under high salt conditions
such as Ni-B (800mM NaCl) the electrostatic interaction between protein and nucleic acids can
be disrupted. The salt concentration could then have been the limiting factor for the low level of
protein-RNA binding seen. Given the promising EMSA results, a dialysis was attempted into a
lower salt buffer pH adjusted with the consideration of thermal shift results (300mM NaCl,
50mM Tris-HCl pH 7.5), but this too precipitated.
To increase the degree of RNA binding by the RBD, a greater portion of the RBD or
other components of RGNEF may need to be expressed as well. pMJ5922 was one of the
smallest constructs designed in this project, encompassing RGNEF1428-1546. Analysis of the
AlphaFold structure reveals that this region of the protein is predicted to exist as a single alpha
helix which runs alongside the highly organized LeuR region, as well as a three-strand alpha
helical region spanning RGNEF1200-1411. It is possible that the presence of these highly organized
regions helps with the stability and RNA binding function of the RBD, or that the full extent of
RNA binding cannot been seen without a larger portion of the RBD. Despite this, results showed

76

that a section of the RGNEF RBD could be successfully purified and was able to maintain the
same RNA binding function as seen in in vivo functional studies56.

4.5 Future Directions
The work in this project documents the first time that the LeuR and RBD of RGNEF have
been successfully purified, allowing for the investigation of the TDP-43/LeuR interaction using
SPR and validation of the RNA binding function in an ex vivo setting. The development of a
protocol for the purification of both the LeuR and RBD of RGNEF lays the foundation for future
work examining the nature of the interaction between RGNEF/TDP-43, pathologic implications
of RGNEF aggregation, and structure of RGNEF.
To further the work done investigating the interaction between the LeuR and TDP-43,
future purifications of LeuR constructs should run native-PAGE gels in addition to postpurification SDS-PAGE gels in order to determine whether or not purified proteins are forming
higher-order structures. This could be further elucidated by analytical ultracentrifugation
sedimentation velocity, or SEC-MALS with the use of a broader resolution column. These
results could influence the interpretation of earlier SPR results, if in fact the TDP-43 binding site
may have been precluded. Additionally, FL-TDP-43 should be purified and used for the purpose
of SPR. As mentioned (4.3 Purified pMJ5899 Does Not Bind TDP-43 in-vitro), binding of TDP43 to RGNEF may depend on the presence of a larger TDP-43 region.
Future work on the RBD should look to purify a broader-spanning construct of the RBD
to analyze whether RNA binding ability increases with the expression of a larger section of the
domain. Purified constructs should undergo pH and salt thermal shift to determine optimal buffer
conditions for subsequent work, followed by replication of the ESMA experiment. If possible,
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ESMA should be performed at a lower salt concentration to optimize the possibility of proteinnucleic acid interactions.
Finally, purified RGNEF constructs should be analyzed using structural biology
techniques such as x-ray crystallography or nuclear magnetic resonance spectroscopy to validate
the predicted structure now available on AlphaFold. Ideally, constructs purified using the
pDEST566 vector should have the 6xHis-MBP tag removed to reduce any flexibility
disorganization which may reduce the ability of pure protein to form crystals; however, if not
possible, the number of structures uploaded to the PDB with the inclusion of fusion tags has been
increasing over the past few years and would still aid in the validation of the AlphaFold
structure. Once validated, both wet lab and virtual techniques could be used to help develop
therapeutic intervention inhibiting the aggregation of RGNEF, reducing NCI load and
maintenance of RGNEF pro-survival effects.
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